WO2023154896A2 - Trkb ligand conjugated compounds and uses thereof - Google Patents

Trkb ligand conjugated compounds and uses thereof Download PDF

Info

Publication number
WO2023154896A2
WO2023154896A2 PCT/US2023/062436 US2023062436W WO2023154896A2 WO 2023154896 A2 WO2023154896 A2 WO 2023154896A2 US 2023062436 W US2023062436 W US 2023062436W WO 2023154896 A2 WO2023154896 A2 WO 2023154896A2
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
compound
salt
prodrug
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/062436
Other languages
English (en)
French (fr)
Other versions
WO2023154896A3 (en
Inventor
Chandramouli CHIRUTA
Huey-Jing Huang
Zhen Li
Rui ZHU
Mihai Azimioara
Bo Cheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AdaRx Pharmaceuticals Inc
Original Assignee
AdaRx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202380033092.0A priority Critical patent/CN118973616A/zh
Application filed by AdaRx Pharmaceuticals Inc filed Critical AdaRx Pharmaceuticals Inc
Priority to KR1020247029980A priority patent/KR20240159828A/ko
Priority to EP23753724.6A priority patent/EP4475837A2/en
Priority to AU2023218398A priority patent/AU2023218398A1/en
Priority to IL314847A priority patent/IL314847A/en
Priority to JP2024547694A priority patent/JP2025506186A/ja
Priority to CA3251455A priority patent/CA3251455A1/en
Priority to US18/837,377 priority patent/US20250161459A1/en
Publication of WO2023154896A2 publication Critical patent/WO2023154896A2/en
Publication of WO2023154896A3 publication Critical patent/WO2023154896A3/en
Anticipated expiration legal-status Critical
Priority to MX2024009892A priority patent/MX2024009892A/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Definitions

  • oligomeric compounds such as, for example, proteins, peptides, antibodies, and oligonucleotides.
  • Oligomeric compounds that include nucleotide sequences (e.g., oligonucleotides) at least partially complementary to a target nucleic acid have been shown to alter the function and activity of the target both in vitro and in vivo.
  • a target nucleic acid such as mRNA or pre-mRNA
  • oligonucleotides When delivered to a cell containing a target nucleic acid (such as mRNA or pre-mRNA), oligonucleotides have been shown to modulate the expression or activity of the target nucleic acid.
  • the oligonucleotide can reduce the expression of the gene by inhibiting translation of the nucleic acid target and/or triggering the degradation of the target nucleic acid.
  • RNA interference is a biological process by which RNA or RNA-like molecules (such as chemically modified RNA molecules) are able to silence gene expression, at least in part, through the RNA-induced silencing Complex (RISC) pathway.
  • RISC RNA-induced silencing Complex
  • oligonucleotides can modulate the expression of a target nucleic acid, such as a target mRNA, through an RNase recruitment mechanism, microRNA mechanisms, occupancy-based mechanisms, and editing mechanisms.
  • Oligonucleotides may be single- stranded or double-stranded.
  • Oligonucleotides may comprise DNA, RNA, and RNA-like molecules, which can also include modified nucleosides including one or more non-phosphodiester linkages.
  • Another class of compounds that can be targeted using targeting ligands are small molecule compounds.
  • the small molecule compounds e.g., an organic compound having a molecular weight of ca. 1000 daltons or less
  • the small molecule compounds are typically shown to alter the function and/or activity of the target such that disease and/or disease symptoms are modulated or ameliorated or are typically useful as a diagnostic marker when localized to the target.
  • More efficient delivery of a compound to a specific location can limit or potentially eliminate unintended consequences (such as off-target effects) that may be caused by administration of the compound and provide improved localization of a diagnostic compound.
  • Embodiments provided herein are directed to compounds (e.g., any of those delineated herein) and methods for targeting cells expressing Tropomyosin Receptor Kinase B (TrkB). Certain embodiments provided herein are directed to compounds and methods for delivering an agent to cells expressing TrkB.
  • the cell is in the brain. In certain embodiments, the cell is in the frontal cortex. In certain embodiments, the cell is in the striatum. In certain embodiments, the cell is in the cerebellum. In certain embodiments, the cell is in the brain stem. In certain embodiments, the cell is in the hippocampus. In certain embodiments, the cell is in the spinal cord. In certain embodiments, the agent is a therapeutic compound.
  • delivery of the agent is for the treatment of diseases, disorders, and symptoms in a subject.
  • the agent is a diagnostic compound.
  • a compound comprises a TrkB ligand and one or more linker moieties for attachment to a therapeutic, prophylactic, or diagnostic agent.
  • a compound comprises a TrkB ligand, one or more linker moieties, and a therapeutic agent.
  • the therapeutic agent is selected from a small molecule or oligomeric compound.
  • the oligomeric compound is a protein, peptide, antibody, oligonucleotide, or combination thereof.
  • the TrkB ligand is a TrkB agonist.
  • the TrkB ligand is a small molecule, aptamer, peptide, or antibody. In certain embodiments, the TrkB ligand is a flavone, tropoflavin, or derivative thereof. In certain embodiments, the TrkB ligand is ANA- 12. In certain embodiments, the TrkB ligand is any of those delineated herein or a prodrug thereof.
  • contacting a cell expressing TrkB, such as a brain cell, with a compound provided herein delivers the agent to the cell.
  • contacting a cell expressing TrkB, such as a brain cell, with a compound provided herein treats a disease, disorder, or symptom in a subject.
  • a compound comprising a TrkB ligand selectively or preferentially targets a cell expressing TrkB compared to a cell not expressing TrkB.
  • a compound comprising a TrkB ligand selectively or preferentially targets a cell expressing TrkB compared to a compound not comprising a TrkB ligand.
  • Certain embodiments provided herein are directed to compounds and methods for modulating expression of a nucleic acid target in cells expressing TrkB.
  • the cell is in the brain. In certain embodiments, the cell is in the frontal cortex. In certain embodiments, the cell is in the striatum. In certain embodiments, the cell is in the cerebellum. In certain embodiments, the cell is in the brain stem. In certain embodiments, the cell is in the hippocampus. In certain embodiments, the cell is in the spinal cord. In certain embodiments, contacting a cell expressing TrkB, such as a brain cell, with a compound provided herein, modulates the expression or activity of a nucleic acid target in the cell. In certain embodiments, a compound comprises a TrkB ligand, one or more linker moieties, and an oligonucleotide.
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (V):
  • Formula (V) wherein: each are independently a Tropomyosin receptor B (TrkB) ligand; each of L 1 , L 2 , L 3 , L 4 , L 1 , L 2 , L 3 , and L 4 is independently a linker, bond, or absent;
  • TrkB Tropomyosin receptor B
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide; zl is 1, 2, or 3; and zl' is 0, 1, 2, or 3.
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (I):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (I'):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (VI):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (VI'):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (II):
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide;
  • R 2 is hydrogen, -OR 7 , -SR 8 , or -NR 9 R 10 ;
  • R 3 is hydrogen, -OR 31 , -SR 32 , or -NR 33 R 34 ;
  • R 4 is hydrogen, -OR 35 , -SR 36 , or -NR 37 R 38 ;
  • R 5 is hydrogen, -OR 39 , -SR 40 , or -NR 41 R 42 ;
  • R 7 , R 8 , R 9 , R 10 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , and R 42 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl; Y is CH 2 , NH, S, or O; and
  • Z is optionally substituted aryl or optionally substituted heteroaryl.
  • R 7 , R 8 , R 9 , R 10 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , and R 42 are each independently optionally substituted unsaturated or partially unsaturated alkyl.
  • R 7 , R 8 , R 9 , and R 10 are each independently alkenyl.
  • R 7 , R 8 , R 9 , and R 10 are each independently alkynyl.
  • R 2 is OR 7 .
  • R 3 is OR 31 .
  • R 7 and R 31 are each independently hydrogen, optionally substituted alkyl, or optionally substituted alkenyl. In certain embodiments, one or both of R 7 and R 31 are independently hydrogen. In certain embodiments, one or both of R 7 and R 31 are independently optionally substituted alkyl. In certain embodiments, one or both of R 7 and R 31 are independently optionally substituted unsaturated or partially unsaturated alkyl. In certain embodiments, one or both of R 7 and R 31 are independently alkenyl. In certain embodiments, R 7 is optionally substituted alkyl and R 31 is hydrogen. In certain embodiments, R 7 is hydrogen and R 31 is optionally substituted alkyl . In certain embodiments, R 7 is alkenyl and R 31 is hydrogen. In certain embodiments, R 7 is hydrogen and R 31 is optionally substituted alkenyl.
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (II- a):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (Il-b):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (II-c): wherein L 1 , L 2 , L 3 , L 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Y, and Z are as described herein.
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (III):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (Ill-a):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (Ill-b): Formula (Ill-b), wherein L 1 , L 2 , L 3 , L 4 , and R 1 are as described herein.
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (III-c):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (III-c- 1):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (IF):
  • R 2 is hydrogen, -OR 7 , -SR 8 , or -NR 9 R 10 ;
  • R 3 is hydrogen, -OR 31 , -SR 32 , or -NR 33 R 34 ;
  • R 4 is hydrogen, -OR 35 , -SR 36 , or -NR 37 R 38 ;
  • R 5 is hydrogen, -OR 39 , -SR 40 , or -NR 41 R 42 ;
  • R 7 , R 8 , R 9 , R 10 ', R 31 , R 32 , R 33 , R 34 ', R 35 , R 36 , R 37 , R 38 , R 39 , R 40 ', R 41 , and R 42 ' are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl;
  • Y is CH 2 , NH, S, or O
  • Z is optionally substituted aryl or optionally substituted heteroaryl.
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (IV): wherein L 1 , L 2 , L 3 , L 4 , and R 1 are as described herein.
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (IV-a):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (IV-b):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (VII): wherein:
  • L 1 , L 2 , L 3 , L 4 , and R 1 are as described herein;
  • R 11 and R 13 are each independently absent, hydrogen, or optionally substituted alkyl
  • R 12 , R 14 , and R 15 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 16 is hydrogen, halogen, -CN, -N 3 , -SO ni6 R 1A , -SO v i6NR 16B R 16C , -NHNR 16B R 16C , -ONR 16B R 16C , -NHC(O)NHNR 16B R 16C , -NHC(O)NR 16B R 16C , -N(0)mi6, -NR 16B R 16C , - C(O)R 16D , -C(O)OR 16D , -C(O)NR 16B R 16C , -OR 16A , -NR 16B SO 2 R 16A , -NR 16B C(O
  • R 16A , R 16B , R 16C , R 16D are each independently hydrogen, halogen, -CF3, -CCI3, -CBr 3 , -CI3,- COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 16B and R 16C substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; z3 is 0, 1, 2, 3, 4, or 5; nl6 is 0, 1, 2, 3, or 4; and vl6 and ml 6 are each independently 1 or 2.
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (Vll-a), Formula (Vll-b), or a mixture thereof:
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (VII-c):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (VII-c- 1), Formula (VII-c-2), or a mixture thereof:
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (VII-d-1), Formula (VII-d-2), or a mixture thereof:
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (II"):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (II'"):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (VIII):
  • R 17 , R 18 , and R 19 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; z4 is 0, 1, or 2; and z5 is 0, 1, 2, or 3. [0040] In one aspect, the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (VIII- a):
  • L 1 , L 2 , L 3 , L 4 , and R 1 are as described herein; and R 18 1 is hydrogen, optionally substituted alkyl or optionally substituted heteroalkyl.
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (VIII-a-1): wherein L 1 , L 2 , L 3 , L 4 , and R 1 are as described herein.
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (IX):
  • R 20 is hydrogen, halogen, -CN, -N 3 , -SO n20 R 1A , -SO V 2oNR 20B R 20C , -NHNR 20B R 20C , -ONR 20B R 20C , -NHC(O)NHNR 20B R 20C , -NHC(O)NR 20B R 20C , -N(O)m20, -NR 20B R 20C , -C(O)R 20D , -C(O)OR 20D , -C(O)NR 20B R 20C , -OR 20A , -NR 20B SO 2 R 20A , -NR 20B C(O)R 20D ;
  • R 21 is hydrogen, halogen, -CN, -N 3 , -SO n2 iR 1A , -SO V 2iNR 21B R 21c , -NHNR 21B R 21C
  • -ONR 21B R 21C -NHC(O)NHNR 21B R 21C , -NHC(O)NR 21B R 21C , -N(0)m2i, -NR 21B R 21C , -C(O)R 21D , -C(O)OR 21D , -C(O)NR 21B R 21C , -0R 21A , -NR 21B SO 2 R 21A , -NR 21B C(O)R 21D ;
  • -NR 21B C(O)OR 21D optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 22 and R 23 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 24 is hydrogen, halogen, -CN, -N 3 , -SO n 2 4 R 24A , -SO V 24NR 24B R 24C , -NHNR 24B R 24C , -ONR 24B R 24C , -NHC(O)NHNR 24B R 24C , -NHC(O)NR 24B R 24C , -N(O)m24, -NR 24B R 24C , -C(O)R 24D , -C(O)OR 24D , -C(O)NR 24B R 24C , -OR 24A , -NR 24B SO 2 R 24A , -NR 24B C(O)R 24D ;
  • -NR 24B C(O)OR 24D -NR 24B OR 24D , optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 20A , R 20B , R 20C , R 20D , R 21A , R 21B , R 21C , R 21D , R 24A , R 24B , R 24C , and R 24D are each independently hydrogen, halogen, -CF3, -CCI3, -CBr 3 , -CI3 -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 20B , R 20C , R 21B , R 21C , R 24B , R 24C , R 24B , and R 2 4C substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (IX-a): (IX-a), wherein L 1 , L 2 , L 3 , L 4 , R 1 , R 20 , R 21 , R 22 , R 24 , z6, z7, and z8 are as described herein.
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (IX-a-1):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (IX-a-2):
  • R 16 , R 20 , R 21 , R 24 are each independently -OH.
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (X): (X), wherein L 1 , L 2 , L 3 , L 4 , and R 1 are as described herein.
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (X-a): wherein L 1 , L 2 , L 3 , L 4 , and R 1 are as described herein.
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (XI):
  • the present disclosure provides compounds, or a stereoisomer, tautomer, prodrug, or salt thereof, of Formula (Xl-a):
  • the present disclosure provides precursor compounds, or a stereoisomer, tautomer, or salt thereof, of Formulae (A)-(F):
  • zl is 1; and zl' is 0 or 1. In certain embodiments, zl is 1 and zl' is 0. In certain embodiments, zl and zl' are each independently 1.
  • the TrkB ligand comprises a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted cycloalkyl. In certain embodiments, the TrkB ligand comprises a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.
  • the TrkB ligand comprises a substituted or unsubstituted mono- or polycyclic aryl, substituted or unsubstituted mono- or polycyclic heteroaryl, substituted or unsubstituted mono- or polycyclic heterocycloalkyl, or substituted or unsubstituted mono- or polycyclic cycloalkyl.
  • the substituted or unsubstituted polycyclic aryl, substituted or unsubstituted polycyclic heteroaryl, substituted or unsubstituted polycyclic heterocycloalkyl or substituted or unsubstituted mono- or polycyclic cycloalkyl are a fused ring system.
  • the fused ring system comprises two to four fused rings. In certain embodiments, the fused ring system further comprises an optionally substituted pendant cycloalkyl, optionally substituted pendant heterocycloalkyl, optionally substituted pendant aryl, or an optionally substituted pendant heteroaryl
  • each TrkB ligand is independently:
  • each TrkB ligand is independently flavone, tropoflavin, or a derivative thereof.
  • each TrkB ligand is independently 3,7-dihydroxyflavone, 3,7,8,2'-tetrahydroxyflavone, 7,3'-dihydroxyflavone, 7,8,2'-trihydroxyflavone, 7,8,3'- trihydroxyflavone, 7,8,4'-trihydroxyflavone, diosmetin (5,7,3'-trihydroxy-4'-methoxyflavone), 7- hydroxy-4'-methoxyflavone, 8-hydroxy-7-methoxyflavone, eutropoflavin (4'-dimethylamino-7,8- dihydroxy flavone), norwogonin (5,7,8-trihydroxyflavone), R7, R13, tropoflavin (7,8- dihydroxy flavone), quercetin (3,3',4',5,7-pentahydroxyflavone), apigenin (4',5,7- trihydroxy flavone), isocoumarin,
  • R 2 is -OH, -O-alkyl, or -O-alkenyl
  • R 3 is -OH, -O-alkyl, or -O-alkenyl.
  • R 2 is -OH.
  • R 3 is -OH.
  • R 4 is hydrogen.
  • R 5 is hydrogen.
  • Y is O.
  • Z is optionally substituted aryl.
  • Z is optionally substituted phenyl.
  • Z is unsubstituted phenyl.
  • Z is phenyl substituted with one or more -OH and/or -O-alkyl.
  • the TrkB ligand is ANA-12, or a prodrug or derivative thereof.
  • R 16 is -NR 16B R 16C ; and R 16B and R 16C are each independently hydrogen or optionally substituted alkyl.
  • R 16B is hydrogen; and R 16C is C1-C3 alkyl.
  • R 16C is -CH3.
  • R 12 is hydrogen or optionally substituted alkyl.
  • R 12 is hydrogen or C1-C3 alkyl.
  • R 12 is hydrogen or -CH3.
  • R 24B is hydrogen or optionally substituted alkyl.
  • R 24B is C1-C3 alkyl.
  • R 24B is -CH3.
  • the TrkB ligand is a TrkB selective ligand or a TrkB non- selective ligand.
  • L 1 , L 2 , L 3 , L 4 , L 1 , L 2 , L 3 , and L 4 are each independently absent, a bond, an optionally substituted alkyl linker, an optionally substituted polyethylene glycol (PEG) linker, an optionally substituted heteroalkyl linker, or an optionally substituted heteroaryl linker.
  • PEG polyethylene glycol
  • L 1 and L 1 are each independently an optionally substituted heteroaryl linker.
  • L 1 and L 1 are each independently an optionally substituted unsaturated heteroaryl, an optionally substituted heteroaryl or an optionally substituted saturated or partially unsaturated heterocycloalkyl linker.
  • L 1 and L 1 each independently comprise the structure .
  • L 1 and L 1 are each independently an optionally substituted heteroalkyl linker.
  • the optionally substituted heteroalkyl linker is an optionally substituted heteroalkyl or optionally substituted Ci-Cio alkyl chain in which one or more carbon atoms are replaced with O, N, or S.
  • L 1 and L 1 each independently comprise the structure or . In certain embodiments, L 1 and L 1 each independently comprise the structure or -N(CH3)-. In certain embodiments, L 2 and L 2 are each independently an optionally substituted PEG linker. [0069] In certain embodiments, the PEG linker is five PEG units in length. In certain embodiments, the PEG linker is four PEG units in length. In certain embodiments, the PEG linker is three PEG units in length.
  • L 2 and L 2 are each independently an optionally substituted alkyl linker. In certain embodiments, L 2 and L 2 are each independently an optionally substituted Ci-20 alkyl linker. In certain embodiments, L 2 and L 2 are each independently an optionally substituted Cs alkyl linker. In certain embodiments, L 3 and L 3 are each independently is an optionally substituted heteroaryl linker.
  • L 3 and L 3 are each independently an optionally substituted partially unsaturated heteroaryl linker, an optionally substituted heteroaryl or an optionally substituted saturated or partially unsaturated heterocycloalkyl linker.
  • L 3 and L 3 each independently comprise the structure
  • L 4 and L 4 are each independently an optionally substituted heteroalkyl linker.
  • the heteroalkyl linker comprises two substituents joined together to form an optionally substituted carbocyclyl ring.
  • L 4 and L 4 each independently comprise the structure salt thereof, wherein X is O or S.
  • L 4 and L 4' each independently comprise the structure: is [0077]
  • L 1 – L 2 –L 3 –L 4 ; or L 1' –L 2' –L 3' –L 4' each independently comprise the structure: , ,
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide
  • X is O or S.
  • a compound, or a stereoisomer, tautomer, prodrug, or salt thereof comprising the structure:
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide
  • X is O or S.
  • a compound, or a stereoisomer, tautomer, prodrug, or salt thereof comprising the structure:
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide
  • X is O or S.
  • a compound, or a stereoisomer, tautomer, prodrug, or salt thereof comprising the structure: wherein:
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide
  • X is O or S.
  • X is O. In certain embodiments, X is S.
  • R 1 comprises an oligonucleotide. In certain embodiments, the oligonucleotide is attached at its 5' end. In certain embodiments, the oligonucleotide is attached at its 3' end. In certain embodiments, the oligonucleotide is attached at an internal position on the oligonucleotide. In certain embodiments, the internal position is an intemucleoside linkage. [0084] In certain embodiments, R 1 comprises an oligonucleotide conjugated to one or more additional TrkB ligands. In certain embodiments, the oligonucleotide is conjugated to two, three, four, five, or more than five additional TrkB ligands.
  • the additional TrkB ligands are conjugated to the oligonucleotide at the 5' end of the oligonucleotide, the 3' end of the oligonucleotide, the 5'- and 3' ends of the oligonucleotide, one or more internal positions on the oligonucleotide, or any combination thereof.
  • the oligonucleotide is a modified oligonucleotide.
  • a compound, or a stereoisomer, tautomer, prodrug, or salt thereof comprising the structure:
  • a compound, or a stereoisomer, tautomer, prodrug, or salt thereof comprising the structure:
  • the compounds disclosed herein are in salt form.
  • salt is a potassium salt or a sodium salt.
  • composition comprising a compound disclosed herein and a pharmaceutically acceptable excipient.
  • a method for delivering a therapeutic oligonucleotide to the brain of a subject comprising administration of a compound disclosed herein, or a stereoisomer, tautomer, prodrug, or salt thereof, to the subject.
  • the therapeutic oligonucleotide is delivered to one or more brain regions selected from the group consisting of the striatum, the cerebellum, the brain stem, the hippocampus, the frontal cortex, and the spinal cord.
  • a method for treating or ameliorating a disease, disorder, or symptom thereof in a subject comprising administration of a compound disclosed herein, or a stereoisomer, tautomer, prodrug, or salt thereof.
  • a method for treating or ameliorating a disease, disorder, or symptom thereof in a subject comprising administration of a composition comprising a compound disclosed herein, or a stereoisomer, tautomer, prodrug, or salt thereof, and a pharmaceutically acceptable excipient.
  • the disease, disorder, or symptom thereof is a central nervous system (CNS) disease, disorder, or symptom thereof.
  • the disease, disorder, or symptom thereof is Alzheimer’s disease, or a symptom thereof.
  • the administration is intrathecal administration or intracerebroventricular (ICV) administration.
  • a method of delivering one or more cargo molecules to a cell or tissue of a subject in vivo comprising administering to the subject a compound disclosed herein, or a stereoisomer, tautomer, prodrug, or salt thereof.
  • a method of delivering one or more cargo molecules to a cell or tissue of a subject in vivo comprising administering to the subject a composition comprising a compound disclosed herein, or a stereoisomer, tautomer, prodrug, or salt thereof.
  • the cell or tissue is CNS cell or tissue.
  • a method of making a compound, or a stereoisomer, tautomer, prodrug, or salt thereof comprising contacting a precursor compound of any one of structural Formulae (A)-(F) disclosed herein with a compound of structural Formula (G) and/or (H): salt thereof, wherein:
  • X 7 and X 8 are each independently O or S;
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide.
  • the present disclosure provides methods for making any of the compounds provided herein, comprising one or more compounds and chemical transformations described herein, including Examples 2-29. DETAILED DESCRIPTION
  • the term “treating” a disorder encompasses ameliorating, mitigating and/or managing the disorder and/or conditions that may cause the disorder.
  • the terms “treating” and “treatment” refer to a method of alleviating or abating a disease and/or its attendant symptoms.
  • “treating” includes blocking, inhibiting, attenuating, protecting against, modulating, reversing the effects of, and reducing the occurrence of, e.g., the harmful effects of a disorder.
  • “inhibiting” encompasses preventing, reducing, and halting progression.
  • isolated refers to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high-performance liquid chromatography (HPLC). Particularly, in certain embodiments, the compound is at least 85% pure, more preferably at least 90% pure, more preferably at least 95% pure, and most preferably at least 99% pure.
  • administration includes routes of introducing the compound(s) to a subject to perform their intended function.
  • routes of administration include injection (subcutaneous, intravenous, parenterally, intraperitoneally, intrathecal), topical, oral, inhalation, rectal, and transdermal.
  • an effective amount includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result.
  • An effective amount of compound may vary according to factors such as the disease state, age, and weight of the subject, and the ability of the compound to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response.
  • An effective amount is also one in which any non-tolerable or detrimental effects (e.g., side effects) of the compound are outweighed by the therapeutically beneficial effects.
  • systemic administration means the administration of a compound(s), oligonucleotide(s), drug, or other material, such that it enters the patient’s circulatory system and, thus, is subject to metabolism and other like processes.
  • terapéuticaally effective amount refers to the amount of the compound being administered sufficient to prevent development of or alleviate to some extent one or more of the symptoms of the condition or disorder being treated.
  • a therapeutically effective amount of compound may range from about 0.005 pg/kg to about 200 mg/kg, preferably about 0.01 mg/kg to about 200 mg/kg, and more preferably about 0.015 mg/kg to about 30 mg/kg of body weight. In other embodiments, the therapeutically effect amount may range from about 1.0 pM to about 10 pM. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present.
  • treatment of a subject with a therapeutically effective amount of a compound can include a single treatment or, preferably, can include a series of treatments.
  • a subject is treated with a compound in the range of between about 0.005 pg/kg to about 200 mg/kg of body weight, daily, weekly, monthly, quarterly, or yearly.
  • a subject may be treated daily, weekly, monthly, quarterly, or yearly for several years in the setting of a chronic condition or illness. It will also be appreciated that the effective dosage of a compound used for treatment may increase or decrease over the course of a particular treatment.
  • chiral refers to molecules that have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules that are superimposable on their mirror image partner.
  • Certain compounds of the present disclosure possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)-for amino acids, and individual isomers are encompassed within the scope of the present disclosure.
  • the compounds of the present disclosure do not include those that are known in art to be too unstable to synthesize and/or isolate.
  • the present disclosure is meant to include compounds in racemic and optically pure forms.
  • Optically active (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents or resolved using conventional techniques.
  • the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.
  • tautomer refers to one of two or more structural isomers which exist in equilibrium, and which are readily converted from one isomeric form to another.
  • structures depicted herein are also meant to include all stereochemical forms of the structure (i.e., the R and S configurations for each asymmetric center). Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the disclosure.
  • chirally enriched population means a plurality of molecules of identical molecular formula, wherein the number or percentage of molecules within the population that contain a particular stereochemical configuration at a particular chiral center is greater than the number or percentage of molecules expected to contain the same particular stereochemical configuration at the same particular chiral center within the population if the particular chiral center were stereorandom. Chirally enriched populations of molecules having multiple chiral centers within each molecule may contain one or more stereorandom chiral centers.
  • the molecules are modified oligonucleotides. In certain embodiments, the molecules are compounds comprising modified oligonucleotides.
  • structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13 C- or 14 C-enriched carbon are within the scope of this disclosure.
  • “stereorandom chiral center” in the context of a population of molecules of identical molecular formula means a chiral center having a random stereochemical configuration.
  • the number of molecules having the (S) configuration of the stereorandom chiral center may be but is not necessarily the same as the number of molecules having the (R) configuration of the stereorandom chiral center.
  • the stereochemical configuration of a chiral center is considered random when it is the results of a synthetic method that is not designed to control the stereochemical configuration.
  • a stereorandom chiral center is a stereorandom phosphorothioate intemucleoside linkage.
  • diastereomers refers to stereoisomers with two or more centers of dissymmetry and whose molecules are not mirror images of one another.
  • enantiomers refers to two stereoisomers of a compound that are non- superimposable mirror images of one another.
  • An equimolar mixture of two enantiomers is called a “racemic mixture” or a “racemate.”
  • isomers or “stereoisomers” refers to compounds that have identical chemical constitution but differ with regard to the arrangement of the atoms or groups in space.
  • prodrug is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active form of the compound (e.g., biologically active form of a nucleic acid) or analogue thereof as described herein.
  • a biologically active form of the compound e.g., biologically active form of a nucleic acid
  • prodrug refers to a precursor of a biologically active compound (e.g., nucleic acid) or analogue thereof that is pharmaceutically acceptable.
  • a prodrug may be inactive when administered to a subject, but is converted in vivo to an active compound, for example, by hydrolysis.
  • the prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam).
  • a discussion of prodrugs is provided in Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein.
  • prodrug is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs of an active compound, as described herein may be prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound.
  • Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively.
  • prodrugs examples include, but are not limited to glutathione, acyloxy, thioacyloxy, 2-carboalkoxyethyl, disulfide, thiaminal, and enol ester derivatives of a phosphorus atom-modified nucleic acid.
  • pro-oligonucleotide or “pronucleotide” or “nucleic acid prodrug” refers to an oligonucleotide which has been modified to be a prodrug of the oligonucleotide.
  • Phosphonate and phosphate prodrugs can be found, for example, in Wiener et al., “Prodrugs or phosphonates and phosphates: crossing the membrane” Top. Curr. Chem.2015, 360:115-160, the entirety of which is herein incorporated by reference. Prodrugs that are converted to active forms through other mechanisms in vivo are also included. In aspects, the compounds of the present disclosure are prodrugs of any of the formulae herein.
  • subject refers to animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, and the like. In certain embodiments, the subject is a human.
  • the words “comprise,” “comprises,” and “comprising” are used in a non-exclusive sense, except where the context requires otherwise.
  • the term “about,” when referring to a value, is meant to encompass variations of, in some embodiments ⁇ 20%, in some embodiments ⁇ 10%, in some embodiments ⁇ 5%, in some embodiments ⁇ 1%, in some embodiments ⁇ 0.5%, and in some embodiments ⁇ 0.1% from the specified amount, as such variations are appropriate to perform the disclosed methods or employ the disclosed compositions.
  • alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight-chained (z.e., unbranched) or branched carbon chain (or carbon), or combination thereof, which may be fully saturated, mono-, (e.g., alkene or alkenyl) or polyunsaturated (e.g., alkyne or alkynyl) and can include mono-, di- and multivalent radicals, having the number of carbon atoms designated.
  • C1-C24 means 1 to 24 carbon atoms.
  • a specified number of carbon atoms within this range includes, for example, C1-C20 alkyl (having 1-20 carbon atoms), C1-C12 alkyl (having 1-12 carbon atoms) and C1-C4 alkyl (having 1-4 carbon atoms).
  • alkenyl refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing 2 to 12 carbon atoms and at least one carbon-carbon double bond. Alkenyl groups may be optionally substituted with one or more substituents.
  • alkynyl refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing the 2 to 12 carbon atoms and at least one carbon-carbon triple bond. Alkynyl groups may be optionally substituted with one or more substituents.
  • lower alkyl refers to a Ci-Ce alkyl chain.
  • alkyl groups include methyl, ethyl, n-propyl, isopropyl, tert-butyl, and n-pentyl.
  • Alkyl groups may be optionally substituted with one or more substituents.
  • heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and/or S), and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quatemized.
  • the heteroatom(s) e.g., O, N, P, Si, and/or S
  • Heteroalkyl is an uncyclized chain.
  • a heteroalkyl moiety may include one heteroatom (e.g., O, N, S, Si, B, or P).
  • a heteroalkyl moiety may include two optionally different heteroatoms (e.g., O, N, S, Si, B, and/or P).
  • a heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S, Si, B, and/or P).
  • a heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, B, and/or P).
  • a heteroalkyl moiety may include five optionally different heteroatoms (e.g., O, N, S, Si, B, and/or P).
  • a heteroalkyl moiety may include up to 8 or more optionally different heteroatoms (e.g., O, N, S, Si, B, and/or P).
  • heteroalkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, — CH 2 — CH 2 — S— CH 2 — CH 2 — and — CH 2 — S— CH 2 — CH 2 — NH— CH 2 — .
  • heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula — C(O) 2 R' — represents both — C(O) 2 R' — and — R'C(O) 2 — .
  • heteroalkyl groups include those groups that are attached to the remainder of the molecule through a heteroatom, such as — C(O)R', — C(O)NR', — NR'R", — OR', — SR', and/or — SO 2 R'.
  • heteroalkyl is recited, followed by recitations of specific heteroalkyl groups, such as — NR'R" or the like, it will be understood that the terms heteroalkyl and — NR'R" are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as — NR'R” or the like.
  • alkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, — CH 2 CH 2 CH 2 CH 2 — .
  • an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein.
  • a “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
  • alkenylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene.
  • cycloalkyl and heterocycloalkyl mean, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl,” respectively. Cycloalkyl and heterocycloalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1 -cyclohexenyl, 3 -cyclohexenyl, cycloheptyl, and the like.
  • heterocyclo alkyl examples include, but are not limited to, l-(l,2,5,6-tetrahydropyridyl), 1- piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.
  • “Cycloalkyl” is also meant to refer to bicyclic and polycyclic hydrocarbon rings such as, for example, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, etc.
  • haloalkyl refers to an alkyl group that is substituted by one or more halo substituents.
  • haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, bromomethyl, chloromethyl, and 2,2,2-trifluoroethyl.
  • arylalkenyl refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing 2 to 12 carbon atoms and at least one carbon-carbon double bond wherein one or more of the sp 2 -hybridized carbons of the alkenyl unit attaches to an aryl moiety.
  • Alkenyl groups may be optionally substituted with one or more substituents.
  • arylalkynyl refers to an unsaturated hydrocarbon chain that may be a straight chain or branched chain, containing 2 to 12 carbon atoms and at least one carbon-carbon triple bond wherein one or more of the sp-hybridized carbons of the alkynyl unit attaches to an aryl moiety.
  • Alkynyl groups may be optionally substituted with one or more substituents.
  • the sp 2 - or sp-hybridized carbons of an alkenyl group and an alkynyl group, respectively, may optionally be the point of attachment of the alkenyl or alkynyl groups.
  • alkoxy refers to an -O-alkyl substituent.
  • halogen means -F, -Cl, -Br or -I.
  • alkylthio refers to an -S-alkyl substituent.
  • alkoxyalkyl refers to an -alkyl-O-alkyl substituent.
  • haloalkoxy refers to an -O-alkyl that is substituted by one or more halo substituents. Examples of haloalkoxy groups include trifluoromethoxy, and 2,2,2-trifluoroethoxy. [0140]
  • haloalkoxyalkyl refers to an -alkyl-O-alkyl' where the alkyl' is substituted by one or more halo substituents.
  • haloalkylaminocarbonyl refers to a -C(O)-amino-alkyl where the alkyl is substituted by one or more halo substituents.
  • haloalkylthio refers to an -S-alkyl that is substituted by one or more halo substituents. Examples of haloalkylthio groups include trifluoromethylthio, and 2,2,2- trifluoroethy Ithio .
  • haloalkylcarbonyl refers to an -C(O)-alkyl that is substituted by one or more halo substituents. An example of a haloalkylcarbonyl group includes trifluoroacetyl.
  • cycloalkyl refers to a hydrocarbon 3-8 membered monocyclic or 7-14 membered bicyclic ring system having at least one saturated ring or having at least one nonaromatic ring, wherein the non-aromatic ring may have some degree of unsaturation.
  • Cycloalkyl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a cycloalkyl group may be substituted by a substituent.
  • cycloalkyl group examples include cyclopropyl, cyclopentyl, cyclohexyl, cyclobutyl, cycloheptyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like.
  • cycloalkoxy refers to an -O-cycloalkyl substituent.
  • cycloalkoxyalkyl refers to an -alkyl-O-cycloalkyl substituent.
  • cycloalkylalkoxy refers to an -O-alkyl-cycloalkyl substituent.
  • cycloalkylaminocarbonyl refers to an -C(O)-NH-cycloalkyl substituent.
  • aryl refers to a hydrocarbon monocyclic, bicyclic, or tricyclic aromatic ring system.
  • Aryl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, 4, 5 or 6 atoms of each ring of an aryl group may be substituted by a substituent. Examples of aryl groups include phenyl, naphthyl, anthracenyl, fluorenyl, indenyl, azulenyl, and the like.
  • aryloxy refers to an -O-aryl substituent.
  • arylalkoxy refers to an -O-alkyl-aryl substituent.
  • arylalkylthio refers to an -S-alkyl-aryl substituent.
  • arylthioalkyl refers to an -alkyl-S -aryl substituent.
  • arylalkylaminocarbonyl refers to a -C(O)-amino-alkyl-aryl substituent.
  • arylalkylsulfonyl refers to an -S(O)2-alkyl-aryl substituent.
  • arylalkylsulfinyl refers to an -S(O)-alkyl-aryl substituent.
  • aryloxyalkyl refers to an -alkyl-O-aryl substituent.
  • alkylaryl refers to an -aryl-alkyl substituent.
  • arylalkyl refers to an -alkyl-aryl substituent.
  • heteroaryl refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-4 ring heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, and the remainder ring atoms being carbon (with appropriate hydrogen atoms unless otherwise indicated).
  • Heteroaryl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a heteroaryl group may be substituted by a substituent.
  • Heteroaryl groups may be fully unsaturated, or they may be partially unsaturated and partially saturated.
  • Examples of heteroaryl groups include pyridyl, furanyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, imidazolyl thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoquinolinyl, indazolyl, and the like.
  • heteroarylalkyl refers to an -alkyl-heteroaryl substituent.
  • heteroaryloxy refers to an -O-heteroaryl substituent.
  • heteroarylalkoxy refers to an -O-alkyl-heteroaryl substituent.
  • heteroaryloxyalkyl refers to an -alkyl-O-heteroaryl substituent.
  • nitrogen-containing heteroaryl refers to a heteroaryl group having 1-4 ring nitrogen heteroatoms if monocyclic, 1-6 ring nitrogen heteroatoms if bicyclic, or 1-9 ring nitrogen heteroatoms if tricyclic.
  • heterocycloalkyl refers to a nonaromatic 3-8 membered monocyclic, 7-12 membered bicyclic, or 10-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, S, B, P or Si, wherein the nonaromatic ring system is completely saturated.
  • Heterocycloalkyl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a heterocycloalkyl group may be substituted by a substituent.
  • heterocycloalkyl groups include piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, 1,3-dioxolane, tetrahydrofuranyl, tetrahydrothienyl, thiirenyl, and the like.
  • heterocycloalkylalkyl refers to an -alkyl-heterocycloalkyl substituent.
  • alkylamino refers to an amino substituent which is further substituted with one or two alkyl groups.
  • aminoalkyl refers to an alkyl substituent which is further substituted with one or more amino groups.
  • hydroxyalkyl or hydroxylalkyl refers to an alkyl substituent which is further substituted with one or more hydroxyl groups.
  • alkyl or aryl portion of alkylamino, aminoalkyl, mercaptoalkyl, hydroxyalkyl, mercaptoalkoxy, sulfonylalkyl, sulfonylaryl, alkylcarbonyl, and alkylcarbonylalkyl may be optionally substituted with one or more substituents.
  • the symbol denotes the point of attachment of a chemical moiety to the remainder of a molecule or chemical formula.
  • nucleobase refers to nitrogen-containing biological compounds that form nucleosides. They include purine bases and pyrimidine bases. Five nucleobases — adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U) — are referred to as primary or canonical nucleobases. When a nucleobase is listed in a formula definition, it refers to that moiety covalently bonded to the recited formula.
  • modified nucleobase refers to derivatives of a nucleobase.
  • modified nucleobases include, but are not limited to, xanthine, hypoxanthine, 7-methylguanine, 5,6-dihydrouracil, 5-methylcytosine, 5-hydroxymethylcytosine, purine, 2,6-diaminopurine, and 6,8-diaminopurine.
  • xanthine hypoxanthine
  • 7-methylguanine 5,6-dihydrouracil
  • 5-methylcytosine 5-hydroxymethylcytosine
  • purine 2,6-diaminopurine
  • 6,8-diaminopurine 6,8-diaminopurine.
  • substituted nucleoside and “substituent group” means an atom or group that replaces the atom or group of a named parent compound.
  • a substituent of a modified nucleoside is an atom or group that differs from the atom or group found in a naturally occurring nucleoside (e.g., a modified 2'-substituent is any atom or group at the 2'-position of a nucleoside other than H or OH).
  • Substituent groups can be protected or unprotected. Substituents may also be further substituted with other substituent groups and may be attached directly or via a linking group such as an alkyl or hydrocarbyl group to the parent compound.
  • substituted in reference to a chemical functional group means an atom or group of atoms that differs from the atom or group of atoms normally present in the named functional group.
  • substituents on any group can be at any atom of that group, wherein any group that can be substituted (such as, for example, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl, cycloalkyl, heterocycloalkyl) can be optionally substituted with one or more substituents (which may be the same or different), each replacing a hydrogen atom.
  • substituents include, but are not limited to alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, halogen, haloalkyl, cyano, nitro, alkoxy, aryloxy, hydroxyl, hydroxylalkyl, oxo (z.e., carbonyl), carboxyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, aryloxycarbonyl, heteroaryloxy, heteroaryloxycarbonyl, thio, mercapto, mercaptoalkyl, arylsulfonyl, amino, aminoalkyl, dialkylamino, alkylcarbonylamino, alkylaminocarbonyl, alkoxycarbonylamino, alkylamino, arylamino, diary
  • substituents on any group include alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, halogen, haloalkyl, cyano, nitro, alkoxy, aryloxy, hydroxyl, hydroxylalkyl, oxo (z.e., carbonyl), carboxyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkylcarbonyloxy, thiocarbonyl, thio, mercapto, mercaptoalkyl, arylsulfonyl, amino, aminoalkyl, dialkylamino, alkylcarbonylamino, alkylaminocarbonyl, alkoxycarbonylamino, alkylamino, arylamino, diarylamino, alkylcarbonyl, or aryla
  • substituents on any group include alkyl, halogen, haloalkyl, cyano, nitro, alkoxy, hydroxyl, hydroxylalkyl, carboxyl, formyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, thio, mercapto, mercaptoalkyl, amino, aminoalkyl, dialkylamino, alkylcarbonylamino, alkylaminocarbonyl, or alkylamino.
  • protecting group refers to a substituent that is commonly employed to block or protect a particular functionality while reacting other functional groups on the compound, a derivative thereof, or a conjugate thereof, and includes a nitrogen protecting group when attached to a nitrogen atom, or an oxygen protecting group when attached to an oxygen atom.
  • Nitrogen and oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
  • the substituent present on a nitrogen atom is a nitrogen protecting group (also referred to as an amino protecting group).
  • Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
  • Amide nitrogen protecting groups include, but are not limited to, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N- benzoylphenylalanyl derivative, benzamide, p-pheny Ibenzamide, o-nitrophenylacetamide, o- nitrophenoxyacetamide, acetoacetamide, (A'-dithiobenzyloxyacylamino)acetamide, 3-(p- hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o- nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4- chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocin
  • Carbamate nitrogen protecting groups include, but are not limited to, methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9-(2- sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethyl carbamate, 2,7-di-t-butyl- [9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4- methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2- trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), l-(l-adamantyl)-l- methyle
  • Sulfonamide nitrogen protecting groups include, but are not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6,-trimethyl-4- methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl- 4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6- dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide
  • Ts p-toluenesulfonamide
  • Mtr 2,
  • nitrogen protecting groups include, but are not limited to, phenothiazinyl-(10)-acyl derivative, A'-p-toluenesulfonylaminoacyl derivative, A'-phenylaminothioacyl derivative, N- benzoylphenylalanyl derivative, A-acetylmethionine derivative, 4,5-diphenyl-3-oxazolin-2-one, A-phthalimide, A-dithiasuccinimide (Dts), A-2,3-diphenylmaleimide, A-2,5-dimethylpyrrole, A-l,l,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted 1,3-dimethyl- l,3,5-triazacyclohexan-2-one, 5-substituted l,3-dibenzyl-l,3,5-triazacyclohexan-2-one, 1-
  • the substituent present on an oxygen atom is an oxygen protecting group (also referred to as a hydroxyl protecting group).
  • Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
  • oxygen protecting groups include, but are not limited to, methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t–butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p– methoxybenzyloxymethyl (PMBM), (4–methoxyphenoxy)methyl (p–AOM), guaiacolmethyl (GUM), t–butoxymethyl, 4–pentenyloxymethyl (POM), siloxymethyl, 2–methoxyethoxymethyl (MEM), 2,2,2–trichloroethoxymethyl, bis(2–chloroethoxy)methyl, 2– (trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3–bromotetrahydropyranyl, tetrahydrothiopyranyl, 1–methoxycyclohexyl, 4–methoxyte
  • the substituent present on a sulfur atom is a sulfur protecting group (also referred to as a thiol protecting group).
  • Sulfur protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
  • antisense oligonucleotide or “antisense strand” means an oligonucleotide which includes a region that is complementary to a target nucleic acid.
  • composition or “pharmaceutical composition” means a mixture of substances suitable for administering to a subject.
  • a composition may comprise one or more compounds or salt thereof and a sterile aqueous solution.
  • nucleic acid refers to molecules composed of linked monomeric nucleotides or nucleosides.
  • a nucleic acid includes, but is not limited to, ribonucleic acids (RNA), deoxyribonucleic acids (DNA), single- stranded nucleic acids, and double- stranded nucleic acids.
  • nucleobase sequence means the order of contiguous nucleobases in a nucleic acid or oligonucleotide independent of any sugar or intemucleoside linkage.
  • nucleoside means a compound comprising a nucleobase and a sugar moiety.
  • the nucleobase and sugar moiety are each, independently, unmodified or modified.
  • Modified nucleoside means a nucleoside comprising a modified nucleobase and/or a modified sugar moiety. Modified nucleosides include abasic nucleosides, which lack a nucleobase.
  • oligomeric compound means a polymer of linked subunits.
  • subunit refers to an amino acid or peptide bond.
  • subunit refers to a nucleotide, nucleoside, nucleobase, or sugar, or a modified nucleotide, nucleoside, nucleobase, or sugar as provided herein.
  • oligonucleotide means a polymer of linked nucleosides (e.g., polynucleotide, nucleic acid, polymer of nucleotides), each of which can be modified or unmodified, independent from one another.
  • an oligonucleotide may be comprised of ribonucleic acids (e.g., comprised of ribonucleosides), deoxyribonucleic acids (e.g., comprised of deoxyribonucleosides), modified nucleic acids (e.g., comprised of modified nucleobases, sugars, and/or phosphate groups), or a combination thereof.
  • oligonucleotide compounds include single-stranded and double- stranded compounds, such as, oligonucleotides, antisense oligonucleotides, interfering RNA compounds (RNAi compounds), microRNA (miRNA) targeting oligonucleotides and miRNA mimics, occupancy-based compounds (e.g., mRNA processing or translation blocking compounds and splicing compounds).
  • RNAi compounds interfering RNA compounds
  • miRNA microRNA
  • occupancy-based compounds e.g., mRNA processing or translation blocking compounds and splicing compounds.
  • RNAi compounds include double- stranded compounds (e.g., short-interfering RNA (siRNA) and double-stranded RNA (dsRNA)) and single- stranded compounds (e.g., single- stranded siRNA (ssRNA), singlestranded RNAi (ssRNAi), short hairpin RNA (shRNA), and microRNA mimics) which work at least in part through the RNA-induced silencing complex (RISC) pathway resulting in sequence specific degradation and/or sequestration of a target nucleic acid through a process known as RNA interference (RNAi).
  • siRNA short-interfering RNA
  • dsRNA double-stranded RNA
  • shRNA short hairpin RNA
  • RNAi RNA-induced silencing complex
  • RNAi compound is meant to be equivalent to other terms used to describe nucleic acid compounds that are capable of mediating sequence-specific RNA interference, for example, interfering RNA (iRNA), iRNA agent, RNAi agent, small interfering RNA, short interfering RNA, short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically modified siRNA, and others. Additionally, the term “RNAi” is meant to be equivalent to other terms used to describe sequence- specific RNA interference.
  • iRNA interfering RNA
  • iRNA agent interfering RNA agent
  • small interfering RNA small interfering RNA
  • short interfering RNA short interfering RNA
  • short interfering oligonucleotide short interfering nucleic acid
  • short interfering modified oligonucleotide chemically modified siRNA, and others.
  • siRNA chemically modified siRNA
  • target nucleic acid all mean a nucleic acid capable of being targeted by compounds described herein.
  • therapeutic compound includes any pharmaceutical agent or compound that provides a therapeutic benefit to a subject.
  • Therapeutic compounds include nucleic acids, oligomeric compounds, oligonucleotides, proteins, peptides, antibodies, small molecules, and other such agents.
  • Target region means a portion of a target nucleic acid to which one or more compounds is targeted.
  • Targeting moiety means a conjugate group that provides an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ, or region of the body, as, e.g., compared to a compound absent such a moiety.
  • Terminal group means a chemical group or group of atoms that is covalently linked to a terminus of an oligonucleotide.
  • RTK receptor tyrosine kinase
  • Trk tropomyosin-related kinase
  • TrkA Tropomyosin Receptor Kinase A
  • TrkB Tropomyosin Receptor Kinase B
  • TrkC Tropomyosin Receptor Kinase
  • TrkA Tropomyosin Receptor Kinase A or “TrkA,” as may be used interchangeably herein, mean the receptor for Nerve Growth Factor (NGF) protein encoded by the NTRK1 gene.
  • NTF Nerve Growth Factor
  • TrkB brain-derived neurotrophic factor
  • TrkB is also known as tyrosine receptor kinase B, BDNF/NT-3 growth factors receptor and neurotrophic tyrosine kinase, receptor, type 2.
  • TrkC Tropomyosin Receptor Kinase C
  • NT-3 neurotropin-3 protein encoded by the NTF3 gene.
  • the compounds disclosed herein are selective TrkB modulators.
  • the compounds disclosed herein are non-selective TrkB modulators (e.g., pan Trk ABC modulators).
  • the compounds disclosed herein are TrkB agonists.
  • the compounds disclosed herein are TrkB antagonists.
  • sense oligonucleotide or “sense strand” means the strand of a double- stranded compound that includes a region that is substantially complementary to a region of the antisense strand of the double-stranded compound.
  • microRNA and “miRNA,” as may be used interchangeably herein, refer to short (e.g., about 20 to about 24 nucleotides in length) non-coding ribonucleic acids (RNAs) that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding.
  • RNAs ribonucleic acids
  • the primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce a stem-loop precursor miRNA (pre-miRNA) approximately 70 nucleotides in length, which is further processed in the RNAi pathway.
  • pre-miRNA stem-loop precursor miRNA
  • the pre- miRNA is cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products.
  • the mature miRNA is incorporated into an RNA- induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing (z.e., partial complementarity) with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA.
  • RISC RNA- induced silencing complex
  • miRNA 3' untranslated region (UTR) of the target mRNA, which can decrease gene expression by either inhibiting translation (for example, by blocking the access of ribosomes for translation) or directly causing degradation of the transcript.
  • the term z.e., miRNA
  • miRNA may be used herein to refer to any form of the subject miRNA (e.g., precursor, primary, and/or mature miRNA).
  • small interfering RNA refers to RNA molecules that present as non-coding double- stranded RNA (dsRNA) molecules of about 20 to about 24 nucleotides in length and are useful in RNA interference (RNAi).
  • siRNA are often found with phosphorylated 5' ends and hydroxylated 3' ends, which 3' ends typically have a 2-nucleotide overhang beyond the 5' end of the anti-parallel strand (e.g., complementary strand of the dsRNA molecule).
  • siRNA can interfere with the expression of specific genes through binding of target sequences (e.g., target nucleic acid sequences) to which they are complementary and promoting (e.g., facilitating, triggering, initiating) degradation of the mRNA, thereby preventing (e.g., inhibiting, silencing, interfering with) translation.
  • target sequences e.g., target nucleic acid sequences
  • promoting e.g., facilitating, triggering, initiating
  • degradation of the mRNA thereby preventing (e.g., inhibiting, silencing, interfering with) translation.
  • siRNAs base-pair (e.g., full complementarity) to their target mRNA and cleave it, thereby preventing it from being used as a translation template.
  • a miRNA- loaded RISC complex scans cytoplasmic mRNAs for potential complementarity (e.g., partial complementarity) .
  • ADAR recruiting molecule refers to a nucleic acid that is configured to increase the concentration of Adenosine Deaminase Acting on Ribonucleic Acid (ADAR) enzyme in a locality around the nucleic acid.
  • ADAR Ribonucleic Acid
  • an increased concentration is relative to the concentration in a given locality absent the ADAR recruiting molecule.
  • an ADAR recruiting molecule comprises a double-stranded RNA duplex.
  • ADAR targeting molecule refers to a nucleic acid that is configured to direct an ADAR molecule to a desirable location (e.g., locality).
  • direct refers to increasing the concentration of ADAR in the desirable location as compared to the concentration absent the ADAR targeting molecule.
  • the ADAR targeting molecule can be configured to control the desirable location by altering the sequence and/or properties of the nucleic acid (e.g., by modifications to the nucleobase, sugar, phosphate, or other component).
  • an ADAR targeting molecule comprises an ADAR recruiting molecule and a single-stranded guide nucleic acid.
  • an ADAR targeting molecule comprises a double-stranded RNA duplex and a single- stranded guide nucleic acid.
  • the target sequence is at, adjacent to, or in proximity to, a locality where it is desirable to modulate ADAR concentration.
  • the level of complementarity is sufficient to facilitate binding (e.g., annealing) of the single-stranded guide nucleic acid to the target sequence.
  • the compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
  • the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I), or carbon-14 ( 14 C). All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure.
  • isotopic variant refers to a therapeutic agent (e.g., a compound and/or modified oligonucleotide disclosed herein) that contains an unnatural proportion of an isotope at one or more of the atoms that constitute such a therapeutic agent.
  • a therapeutic agent e.g., a compound and/or modified oligonucleotide disclosed herein
  • an “isotopic variant” of a therapeutic agent contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen (H), deuterium ( 2 H), tritium ( 3 H), carbon- 11 ( n C), carbon- 12 ( 12 C), carbon-13 ( 13 C), carbon-14 ( 14 C), nitrogen-13 ( 13 N), nitrogen-14 ( 14 N), nitrogen-15 ( 15 N), oxygen-14 ( 14 O), oxygen-15 ( 15 O), oxygen-16 ( 16 O), oxygen-17 ( 17 O), oxygen-18 ( 18 O), fluorine-17 ( 17 F), fluorine-18 ( 18 F), phosphorus-31 ( 31 P), phosphorus-32 ( 32 P), phosphorus-33 ( 33 P), sulfur-32 ( 32 S), sulfur-33 ( 33 S), sulfur-34 ( 34 S), sulfur-35 ( 35 S), sulfur-36 ( 36 S), chlorine-35 ( 35 C1), chlorine-36 ( 36 C1), chlorine-37 ( 37 C1), bromine-79 ( 79 Br), bromine-81 ( 81 Br), io
  • an “isotopic variant” of a therapeutic agent contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen (H), deuterium ( 2 H), tritium ( 3 H), carbon-11 ( n C), carbon-12 ( 12 C), carbon-13 ( 13 C), carbon-14 ( 14 C), nitrogen-13 ( 13 N), nitrogen-14 ( 14 N), nitrogen-15 ( 15 N), oxygen-14 ( 14 O), oxygen-15 ( 15 O), oxygen-16 ( 16 O), oxygen-17 ( 17 O), oxygen- 18 ( 18 O), fluorine-17 ( 17 F), fluorine-18 ( 18 F), phosphorus-31 ( 31 P), phosphorus-32 ( 32 P), phosphorus-33 ( 33 P), sulfur-32 ( 32 S), sulfur-33 ( 33 S), sulfur-34 ( 34 S), sulfur-35 ( 35 S), sulfur-36 ( 36 S), chlorine-35 ( 35 C1), chlorine-36 ( 36 C1), chlorine-37 ( 37 C1), bromine-79 ( 79 Br), bromine-81 ( 81 Br), iod
  • any hydrogen can be 2 H, for example, or any carbon can be 13 C, for example, or any nitrogen can be 15 N, for example, or any oxygen can be 18 O, for example, where feasible according to the judgment of one of skill.
  • an “isotopic variant” of a therapeutic agent contains unnatural proportions of deuterium (D).
  • Modified oligonucleotide means an oligonucleotide, wherein at least one sugar, nucleobase, or intemucleoside linkage is modified.
  • Nucleobase sequence means the order of contiguous nucleobases in a nucleic acid or oligonucleotide independent of any sugar or intemucleoside linkage.
  • oligomeric duplex means a duplex formed by two oligomeric compounds having complementary nucleobase sequences.
  • Each oligomeric compound of an oligomeric duplex may be referred to as a “duplexed oligomeric compound.”
  • the oligonucleotides of each oligomeric compound of an oligomeric duplex may include non-complementary overhanging nucleosides.
  • duplexed oligomeric compound” and “modified oligonucleotide” are used interchangeably.
  • the terms “oligomeric duplex” and “compound” are used interchangeably.
  • Phosphorothioate linkage means a modified phosphate linkage in which one of the nonbridging oxygen atoms is replaced with a sulfur atom. Modified phosphate linkages where at least one of the oxygen linked to the phosphate has been replaced or the phosphate group has been replaced by a non-phosphorous group, are also referred to as “non-phosphodiester internucleoside linkage” or “non-phosphodiester linker.
  • RNA interference compound means a compound that acts, at least in part, through an RNA-induced silencing complex (RISC) pathway or Ago2, but not through RNase H, to modulate a target nucleic acid and/or protein encoded by a target nucleic acid.
  • RISC RNA-induced silencing complex
  • RNAi compounds include, but are not limited to doublestranded siRNA, single-stranded siRNA, and microRNA, including microRNA mimics.
  • a compound comprises a TrkB ligand and one or more linker moieties.
  • the compound is selected from any of formulae I, I', II, IP, II", II'", Il-a, Il-b, II-c, III, Ill-a, Ill-b, III-c, III-c-1, IV, IV-a, IV-b, V, VI, VI', VII, Vll-a, Vll-b, VII- c, VII-c-1, VII-c-2, Vll-d, VII-d-1, VII-d-2, Vlll-a, VIII-a-1, VIII, IX IX-a, IX-a-1, IX-a-2, X, X- a, XI, and Xl-a, or a salt thereof as described herein.
  • the one or more linker moieties links the TrkB ligand to a therapeutic, prophylactic, or diagnostic agent.
  • the compound further comprises a therapeutic, prophylactic, or diagnostic agent.
  • the therapeutic, prophylactic, or diagnostic agent is a small molecule, or an oligomeric compound.
  • the oligomeric compound comprises a protein, peptide, antibody, oligonucleotide, or combination thereof.
  • an oligomeric compound is any of those described herein. In certain embodiments, the oligomeric compound is about 10-50 subunits in length. In certain embodiments the oligomeric compound is an oligonucleotide. In certain embodiments, an oligonucleotide is any of those described herein. In certain embodiments, the oligonucleotide is 8 to 80 linked nucleosides in length, 12-30 linked nucleosides in length, 12-30 linked nucleosides in length, or 15-30 linked nucleosides in length.
  • the oligonucleotide is a modified oligonucleotide comprising at least one modified internucleoside linkage, at least one modified sugar, or at least one modified nucleobase.
  • the oligonucleotide is single- stranded. In certain embodiments, the oligonucleotide is double-stranded. In certain embodiments, the oligonucleotide comprises ribonucleic acids (e.g., comprised of ribonucleosides), deoxyribonucleic acids (e.g., comprised of deoxyribonucleosides), or a combination thereof.
  • ribonucleic acids e.g., comprised of ribonucleosides
  • deoxyribonucleic acids e.g., comprised of deoxyribonucleosides
  • the oligonucleotide is a small interfering RNA (siRNA), a microRNA (miRNA) antagonist, an miRNA mimic, an ADAR recruiting molecule, an ADAR targeting molecule, a guide RNA, an antisense oligonucleotide, a short hairpin RNA (shRNA), or combinations thereof.
  • siRNA small interfering RNA
  • miRNA microRNA
  • miRNA mimic miRNA mimic
  • ADAR recruiting molecule an ADAR targeting molecule
  • guide RNA an antisense oligonucleotide
  • shRNA short hairpin RNA
  • a linker is an optionally substituted PEG linker.
  • the PEG linker is five PEG units in length.
  • the PEG linker is four PEG units in length.
  • the PEG linker is three PEG units in length.
  • a linker is an optionally substituted alkyl linker.
  • a linker is an optionally substituted Ci-20 alkyl linker.
  • the linker is an optionally substituted Cs alkyl linker.
  • a linker is an optionally substituted heteroaryl linker.
  • a linker is an optionally substituted partially unsaturated heteroaryl linker.
  • a linker comprises the structure wherein X is O or S. In certain embodiments, a linker comprises the structure wherein X is O or S. In certain embodiments, a linker comprises the structure
  • a linker comprises the structure wherein X is O or S. In certain embodiments, a linker comprises the structure wherein X is O or S. In certain embodiments, a linker comprises the structure wherein X is O or S.
  • a compound comprises or consists of one of the structures: , , [0218]
  • X is O.
  • X is S.
  • R 1 comprises an oligonucleotide.
  • the oligonucleotide is attached at its 5′ end.
  • the oligonucleotide is attached at its 3′ end.
  • the oligonucleotide is attached at an internal position on the oligonucleotide. In some embodiments the internal position is at an internucleoside linkage.
  • R 1 comprises an oligonucleotide conjugated to one or more additional TrkB ligands.
  • the oligonucleotide is conjugated to two, three, four, five, or more than five additional TrkB ligands.
  • the additional TrkB ligands are conjugated to the oligonucleotide at the 5′ end of the oligonucleotide, the 3′ end of the oligonucleotide, one or more internal positions on the oligonucleotide, or any combination thereof.
  • the oligonucleotide is a modified oligonucleotide.
  • compositions comprising a compound of any embodiment herein, and a pharmaceutically acceptable carrier or excipient.
  • compositions comprising a compound of any embodiment herein, for use in therapy.
  • a method for delivering an agent to cell comprises contacting the cell with the compound of any embodiments herein, thereby delivering the agent to the cell.
  • the cell expresses TrkB on the surface of the cell.
  • the cell is a brain cell.
  • the cell is a cell of the frontal cortex.
  • the cell is a cell of the striatum.
  • the cell is a cell of the cerebellum.
  • the cell is a cell of the brain stem.
  • the cell is a cell of the hippocampus.
  • the cell is a cell of the spinal cord.
  • the agent is a therapeutic agent or diagnostic agent.
  • the cell is in an animal.
  • a method of modulating the expression of a nucleic acid target in a cell comprises contacting the cell with the compound of any embodiments herein, thereby modulating expression of the nucleic acid target in the cell.
  • the cell expresses TrkB on the surface of the cell.
  • the cell is a brain cell.
  • the cell is a cell of the frontal cortex.
  • the cell is a cell of the striatum.
  • the cell is a cell of the cerebellum.
  • the cell is a cell of the brain stem.
  • the cell is a cell of the hippocampus.
  • the cell is a cell of the spinal cord.
  • the agent is a therapeutic agent or diagnostic agent.
  • contacting the cell with the compound the compound of any embodiments herein inhibits expression of the nucleic acid target.
  • the nucleic acid target is pre- mRNA, mRNA, non-coding RNA, or miRNA.
  • the cell is in an animal.
  • a method of modulating the expression of a nucleic acid target in a subject comprises administering to the subject any of the compounds or compositions provided herein, thereby modulating expression of the nucleic acid target in the subject.
  • the expression of the nucleic acid is modulated in a cell of the subject that expresses TrkB on the surface of the cell.
  • the expression of the nucleic acid is modulated in a brain cell.
  • the cell expressing TrkB on its surface is a brain cell.
  • the brain cell is a cell of the frontal cortex.
  • the brain cell is a cell of the striatum.
  • the brain cell is a cell of the cerebellum. In certain embodiments, the brain cell is a cell of the brain stem. In certain embodiments, the brain cell is a cell of the hippocampus. In certain embodiments, the brain cell is a cell of the spinal cord. In certain embodiments, the nucleic acid target is pre-mRNA, mRNA, non-coding RNA, or miRNA. In certain embodiments, the compound is administered to the subject intrathecally.
  • a method of treating or ameliorating a disease, disorder, or symptom thereof in a subject comprises administering to the subject any of the compounds or compositions provided herein, thereby treating, preventing, or ameliorating a disease, disorder, or symptom in the subject.
  • the disease, disorder, or symptom thereof is a central nervous system (CNS) disease, disorder, or symptom thereof.
  • the disease, disorder, or symptom thereof is Alzheimer’s disease, or a symptom thereof.
  • the compound is administered to the subject intrathecally.
  • the compound or composition is administered to the subject in a therapeutically effective amount.
  • a compound comprising a TrkB ligand selectively or preferentially targets a cell expressing TrkB compared to a cell not expressing TrkB. In certain embodiments, a compound comprising a TrkB ligand selectively or preferentially targets a cell expressing TrkB compared to a compound not comprising a TrkB ligand.
  • Also provided herewith is the use of a compound as described herein for the manufacture of a medicament in the treatment of a disease or disorder.
  • the present disclosure provides methods for making any of the compounds provided herein, comprising one or more compounds and chemical transformations described herein, including Examples 2-29.
  • compounds described herein comprise oligonucleotides.
  • an oligonucleotide has a nucleobase sequence that is at least partially complementary to a target nucleic acid sequence (e.g., an expressed target nucleic acid within a cell).
  • the oligonucleotide upon delivery to a cell expressing a target nucleic acid, is able to inhibit the expression of the underlying gene. The gene expression can be inhibited in vitro or in vivo.
  • an oligonucleotide comprises one or more ribonucleic acids (e.g., one or more ribonucleosides), deoxyribonucleic acids (e.g., one or more deoxyribonucleosides), modified nucleic acids (e.g., one or more modified nucleobases, sugars, and/or phosphate groups), or a combination thereof.
  • an oligonucleotide comprises a ribonucleic acid (RNA).
  • an oligonucleotide comprises a deoxyribonucleic acid (DNA).
  • an oligonucleotide comprises a modification (e.g., modified nucleobase, modified sugar, or modified phosphate).
  • an oligonucleotide is single- stranded.
  • a single- stranded oligonucleotide is single-stranded RNA (ssRNA), ssDNA, or a ssRNA/DNA hybrid (e.g., a single- stranded oligonucleotide comprised of both ribonucleosides (modified or unmodified) and deoxyribonucleosides (modified or unmodified)).
  • ssRNA single-stranded RNA
  • ssDNA single-stranded oligonucleotide comprised of both ribonucleosides (modified or unmodified) and deoxyribonucleosides (modified or unmodified)
  • an oligonucleotide is double- stranded (e.g., comprised of two single- stranded nucleic acids).
  • Such double-stranded oligonucleotides comprise a first oligonucleotide having a region complementary to a target nucleic acid and a second oligonucleotide having a region complementary to the first oligonucleotide.
  • the first and second oligonucleotides can be independently modified.
  • the first oligonucleotide is linked to one or more TrkB ligands.
  • the second oligonucleotide is linked to one or more TrkB ligands.
  • an oligonucleotide is at least 2 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,
  • an oligonucleotide is at least 5 nucleotides in length. In some embodiments, an oligonucleotide is at least 10 nucleotides in length.
  • an oligonucleotide is at least 15 nucleotides in length. In some embodiments, an oligonucleotide is at least 16 nucleotides in length. In some embodiments, an oligonucleotide is at least 17 nucleotides in length. In some embodiments, an oligonucleotide is at least 18 nucleotides in length. In some embodiments, an oligonucleotide is at least 19 nucleotides in length. In some embodiments, an oligonucleotide is at least 20 nucleotides in length. In some embodiments, an oligonucleotide is at least 21 nucleotides in length.
  • an oligonucleotide is at least 22 nucleotides in length. In some embodiments, an oligonucleotide is at least 23 nucleotides in length. In some embodiments, an oligonucleotide is at least 24 nucleotides in length. In some embodiments, an oligonucleotide is at least 25 nucleotides in length. In some embodiments, an oligonucleotide is at least 26 nucleotides in length. In some embodiments, an oligonucleotide is at least 27 nucleotides in length. In some embodiments, an oligonucleotide is at least 28 nucleotides in length.
  • an oligonucleotide is at least 29 nucleotides in length. In some embodiments, an oligonucleotide is at least 30 nucleotides in length. In some embodiments, an oligonucleotide is at least 40 nucleotides in length. In some embodiments, an oligonucleotide is at least 50 nucleotides in length. In some embodiments, an oligonucleotide is at least 60 nucleotides in length. In some embodiments, an oligonucleotide is at least 70 nucleotides in length. In some embodiments, an oligonucleotide is at least 80 nucleotides in length.
  • an oligonucleotide is at least 90 nucleotides in length. In some embodiments, an oligonucleotide is at least 100 nucleotides in length. In some embodiments, an oligonucleotide is at least 150 nucleotides in length.
  • an oligonucleotide is less than or equal to 150 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108,
  • an oligonucleotide is less than or equal to 150 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 100 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 90 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 80 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 70 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 60 nucleotides in length.
  • an oligonucleotide is less than or equal to 50 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 40 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 30 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 29 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 28 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 27 nucleotides in length.
  • an oligonucleotide is less than or equal to 26 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 25 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 24 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 23 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 22 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 21 nucleotides in length.
  • an oligonucleotide is less than or equal to 20 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 19 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 18 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 17 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 16 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 15 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 10 nucleotides in length. In some embodiments, an oligonucleotide is less than or equal to 5 nucleotides in length.
  • an oligonucleotide is about 5 nucleotides in length to about 150 nucleotides in length. In some embodiments, an oligonucleotide is about 10 nucleotides in length to about 100 nucleotides in length. In some embodiments, an oligonucleotide is about 20 nucleotides in length to about 90 nucleotides in length. In some embodiments, an oligonucleotide is about 30 nucleotides in length to about 80 nucleotides in length. In some embodiments, an oligonucleotide is about 40 nucleotides in length to about 70 nucleotides in length. In some embodiments, an oligonucleotide is about 50 nucleotides in length to about 60 nucleotides in length.
  • an oligonucleotide is a therapeutic oligonucleotide.
  • a therapeutic oligonucleotide may comprise, for example, without limitation, a small interfering RNA (siRNA), a microRNA (miRNA) antagonist, a miRNA mimic, an ADAR recruiting molecule, an ADAR targeting molecule, a guide RNA, an antisense oligonucleotide, a short hairpin RNA (shRNA), or combinations thereof.
  • a miRNA is a precursor, primary, and/or mature miRNA.
  • an oligonucleotide comprises or consists of an antisense oligonucleotide.
  • an antisense oligonucleotide is complementary to an mRNA.
  • an antisense oligonucleotide is complementary to a pre-mRNA.
  • an antisense oligonucleotide blocks translation and promotes degradation of the mRNA transcript.
  • an antisense oligonucleotide recruits RNase H and promotes degradation of the mRNA transcript.
  • an antisense oligonucleotide targets miRNA, inhibiting the miRNA from modulating mRNA expression and promoting degradation of the miRNA.
  • oligonucleotides may be unmodified RNA or DNA or may be modified.
  • the oligonucleotides are modified oligonucleotides.
  • the modified oligonucleotides comprise at least one modified sugar, modified nucleobase, or modified intemucleoside linkage relative to an unmodified RNA or DNA.
  • an oligonucleotide has a modified nucleoside.
  • a modified nucleoside may comprise a modified sugar, a modified nucleobase, or both a modified sugar and a modified nucleobase.
  • Modified oligonucleotides may also include end modifications, e.g., 5'-end modifications and 3 '-end modifications.
  • a modified sugar is a substituted furanosyl sugar or non-bicyclic modified sugar.
  • a modified sugar is a bicyclic or tricyclic modified sugar.
  • a modified sugar is a sugar surrogate.
  • a sugar surrogate may comprise one or more substitutions described herein.
  • a modified sugar is a substituted furanosyl or non-bicyclic modified sugar.
  • the furanosyl sugar is a ribosyl sugar.
  • the furanosyl sugar comprises one or more substituent groups, including, but not limited to, substituent groups at the 2', 3', 4', and 5' positions.
  • substituents at the 2' position include, but are not limited to, F and OCH3 (“OMe”, “O-methyl” or “methoxy”).
  • substituent groups at the 2' position suitable for non-bicyclic modified sugars include, but are not limited to, halo, allyl, amino, azido, SH, CN, OCN, CF 3 , OCF3, F, Cl, Br, SCH3, SOCH3, SO2CH3, ONO 2 , NO 2 , N3, and NH2.
  • substituent groups at the 2' position include, but are not limited to, O-(Ci-Cio) alkoxy, alkoxyalkyl, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, O- alkynyl, S-alkynyl, N-alkynyl, O-alkyl-O-alkyl, alkynyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted Ci to C10 alkyl or C2 to C10 alkenyl and alkynyl.
  • substituent groups at the 2' position include, but are not limited to, alkaryl, aralkyl, O-alkaryl, and O-aralkyl. In certain embodiments, these 2' substituent groups can be further substituted with one or more substituent groups independently selected from hydroxyl, alkoxy, carboxy, benzyl, phenyl, nitro (NO2), thiol, thioalkoxy, thioalkyl, halogen, alkyl, aryl, alkenyl, and alkynyl.
  • substituent groups at the 2' position include, but are not limited to, O[(CH 2 ) n O] m CH3, O(CH 2 ) n OCH 3 , O(CH 2 ) n CH 3 , O(CH2) n ONH 2 , O(CH 2 ) n NH 2 , O(CH 2 ) n SCH 3 , and O(CH2) n ON[(CH2) n CH3)]2, where n and m are independently from 1 to about 10.
  • MOE OCH2CH2OCH3
  • DMAOE O(CH 2 )2ON(CH 3 )2
  • DMAEOE O(CH2)2O(CH 2 )2N(CH 3 )2
  • substituent groups at the 4' position suitable for non-bicyclic modified sugars include, but are not limited to, alkoxy (e.g., methoxy), alkyl, and those described in Manoharan et al., WO 2015/106128.
  • substituent groups at the 5' position suitable for non-bicyclic modified sugars include, but are not limited to, methyl (“Me” or “CH3”) (R or S), vinyl, and methoxy.
  • the 5' modification is a 5 '-monophosphate ((HO)2(O)P-O-5'); 5 '-diphosphate ((HO) 2 (O)P-O-P(HO)(O)-O-5'); 5 '-triphosphate ((HO) 2 (O)P-O-(HO)(O)P-O- P(HO)(O)-O-5'); 5'-guanosine cap (7-methylated or non-methylated) (7m-G-O-5'-(HO)(O)P-O- (HO)(O)P-O-P(HO)(O)-O-5'); 5'adenosine cap (Appp), and any modified or unmodified nucleotide cap structure (N-O
  • one or more sugars comprise a 5'-vinylphosphonate modification.
  • the 5' modification is at the terminus of an oligonucleotide.
  • the 5' modification is at the terminus of an antisense oligonucleotide.
  • substituents described herein for the 2', 4', and 5' position can be added to other specific positions on the sugar.
  • such substituents may be added to the 3' position of the sugar on the 3' terminal nucleoside or the 5' position of the 5' terminal nucleoside.
  • a non-bicyclic modified sugar may comprise more than one non-bridging sugar substituent.
  • non-bicyclic modified sugars substituents include, but are not limited to, 5'-Me-2'-F, 5'-Me-2'-OMe (including both R and S isomers).
  • modified sugar substituents include those described in Migawa et al., WO 2008/101157 and Rajeev et al., US2013/0203836.
  • a modified sugar is a bicyclic sugar.
  • a bicyclic sugar is a modified sugar comprising two rings, wherein the second ring is formed via a bridge connecting two of the atoms in the first ring, thereby forming a bicyclic structure.
  • a bicyclic sugar comprises a bridging substituent that bridges two atoms of the furanosyl ring to form a second ring.
  • a bicyclic sugar does not comprise a furanosyl moiety.
  • a “bicyclic nucleoside” (“BNA”) is a nucleoside having a bicyclic sugar.
  • the bicyclic sugar comprises a bridge between the 4' and 2' furanose ring atoms. In certain embodiments, the bicyclic sugar comprises a bridge between the 5' and 3' furanose ring atoms. In certain such embodiments, the furanose ring is a ribose ring.
  • 4' to 2' bridging substituents include, but are not limited to, 4'-CH2-2', 4'-(CH2)2-2', 4'- (CH2)3-2', 4'- CH 2 -O-2' (“LNA”), 4'-CH 2 -S-2', 4'-(CH 2 )2-O-2' (“ENA”), 4'-CH(CH 3 )-O-2' (“constrained ethyl” or “cEt” when in the S configuration), 4'-CH2-O-CH 2 -2', 4'-CH 2 -N(R)-2', 4'- CH(CH 2 OCH 3 )-O- 2' (“constrained MOE” or “cMOE”) and analogs thereof (e.g., U.S.
  • Patent No. 7,399,845) 4'- C(CH 3 )(CH 3 )-O-2' and analogs thereof (e.g., U.S. Patent No. 8,278,283), 4'-CH 2 -N(OCH 3 )-2' and analogs thereof (e.g., U.S. Patent No. 8,278,425), 4'-CH 2 -O-N(CH 3 )-2' (e.g., U.S. Patent Publication No. 2004/0171570), 4'-CH2-N(R)-O-2', wherein R is H, C1-C12 alkyl, or a protecting group (e.g., U.S. Patent No.
  • bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including, for example, a-L-ribofuranose and P-D- ribofuranose (see, e.g., WO 99/14226). Specified bicyclic nucleosides herein are in the P-D configuration, unless otherwise specified.
  • a modified sugar is a sugar surrogate.
  • a sugar surrogate has the oxygen atom replaced, e.g., with a sulfur, carbon or nitrogen atom.
  • the sugar surrogate may also comprise bridging and/or non-bridging substituents as described herein.
  • sugar surrogates comprise rings having other than 5 atoms.
  • the sugar surrogate comprises a cyclobutyl moiety in place of the pentofuranosyl sugar.
  • the sugar surrogate comprises a six membered ring in place of the pentofuranosyl sugar.
  • the sugar surrogate comprises a tetrahydropyran (“THP”) in place of the pentofuranosyl sugar.
  • the sugar surrogate comprises a morpholino in place of the pentofuranosyl sugar.
  • THP tetrahydropyran
  • Representative U.S. Patent Nos that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Patent Nos. 4,981,957; 5,118,800; 5,166,315; 5,185,444;
  • sugar surrogates comprise acyclic moieties.
  • the sugar surrogate is an unlocked nucleic acid (“UNA”).
  • UNA is unlocked acyclic nucleic acid, wherein any of the bonds of the sugar has been removed, forming an unlocked "sugar” residue.
  • UNA also encompasses a monomer where the bonds between Cl'-C4' have been removed (z.e., the covalent carbon-oxygen-carbon bond between the Cl' and C4' carbons).
  • the C2'-C3' bond z.e., the covalent carbon-carbon bond between the C2' and C3' carbons
  • sugar surrogates comprise peptide nucleic acid (“PNA”), acyclic butyl nucleic acid (see, e.g., Kumar et al., Org. Biomol. Chem., 2013, 11, 5853-5865), and nucleosides and oligonucleotides described in Manoharan et al., US2013/130378, the entire contents of which is hereby incorporated herein by reference.
  • PNA peptide nucleic acid
  • acyclic butyl nucleic acid see, e.g., Kumar et al., Org. Biomol. Chem., 2013, 11, 5853-5865)
  • nucleosides and oligonucleotides described in Manoharan et al., US2013/130378, the entire contents of which is hereby incorporated herein by reference.
  • Many other bicyclic and tricyclic sugar and sugar surrogate ring systems are known in the art that can be used in modified nucleosides.
  • the disclosure relates to compounds comprising at least one oligonucleotide wherein the nucleosides of such oligonucleotide comprise one or more types of modified sugars and/or unmodified sugars arranged along the oligonucleotide or region thereof in a defined pattern or “sugar motif’.
  • sugar motifs include, but are not limited to, any of the patterns of sugar modifications described herein.
  • an oligonucleotide comprises a gapmer sugar motif.
  • a gapmer oligonucleotide comprises or consists of a region having two external “wing” regions and a central or internal “gap” region. The gap and wing regions form a contiguous sequence of nucleosides, wherein the majority of nucleoside sugars of each of the wings differ from the majority of nucleoside sugars of the gap.
  • the wing regions comprise a majority of modified sugars and the gap comprises a majority of unmodified sugars.
  • the nucleosides of the gap are deoxynucleosides. Compounds with a gapmer sugar motif are described in, for example, U.S. Patent No. 8,790,919, the entire contents of which is hereby incorporated herein by reference.
  • one or both oligonucleotides of a double-stranded compound comprise a triplet sugar motif.
  • An oligonucleotide with a triplet sugar motif comprises three identical sugar modifications on three consecutive nucleosides.
  • the triplet is at or near the cleavage site of the oligonucleotide.
  • an oligonucleotide of a double- stranded compound may contain more than one triplet sugar motif.
  • the identical sugar modification of the triplet sugar motif is a 2'-F modification.
  • one or both oligonucleotides of a double-stranded compound comprise a quadruplet sugar motif.
  • An oligonucleotide with a quadruplet sugar motif comprises four identical sugar modifications on four consecutive nucleosides.
  • the quadruplet is at or near the cleavage site.
  • an oligonucleotide of a doublestranded compound may contain more than one quadruplet sugar motif.
  • the identical sugar modification of the quadruplet sugar motif is a 2'-F modification.
  • the cleavage site of the antisense oligonucleotide is typically around the 10, 11, and 12 positions from the 5'-end.
  • the quadruplet sugar motif is at the 8, 9, 10, 11 positions; the 9, 10, 11, 12 positions; the 10, 11, 12, 13 positions; the 11, 12, 13, 14 positions; or the 12, 13, 14, 15 positions of the sense oligonucleotide, counting from the first nucleoside of the 5 '-end of the sense oligonucleotide, or, the count starting from the first paired nucleotide within the duplex region from the 5'-end of the sense oligonucleotide.
  • the quadruplet sugar motif is at the 8, 9, 10, 11 positions; the 9, 10, 11, 12 positions; the 10, 11, 12, 13 positions; the 11, 12, 13, 14 positions; or the 12, 13, 14, 15 positions of the antisense oligonucleotide, counting from the first nucleoside of the 5 '-end of the antisense oligonucleotide, or, the count starting from the first paired nucleotide within the duplex region from the 5'- end of the antisense oligonucleotide.
  • the cleavage site may change according to the length of the duplex region of the double- stranded compound and may change the position of the quadruplet accordingly.
  • an oligonucleotide comprises an alternating sugar motif.
  • one or both oligonucleotides of a double-stranded compound comprise an alternating sugar motif.
  • An oligonucleotide with an alternating sugar motif comprises at least two different sugar modifications, wherein one or more consecutive nucleosides comprising a first sugar modification alternates with one or more consecutive nucleosides comprising a second sugar modification, and one or more consecutive nucleosides comprising a third sugar modification, etc.
  • the alternating motif can be “AB AB AB AB AB AB...,” “AABBAABBAABB...,” “AABAABAABAAB “AAABAAABAAAB...,” “AAABBBAAABBB...,” or “ABCABCABCABC...” etc.
  • the alternating sugar motif is repeated for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleobases along an oligonucleotide.
  • the alternating sugar motif is comprised of two different sugar modifications.
  • the alternating sugar motif comprises 2'-0Me and 2'-F sugar modifications.
  • each nucleoside of an oligonucleotide is independently modified with one or more sugar modifications provided herein.
  • each oligonucleotide of a double- stranded compound independently has one or more sugar motifs provided herein.
  • an oligonucleotide containing a sugar motif is fully modified in that each nucleoside other than the nucleosides comprising the sugar motif comprises a sugar modification.
  • modified oligonucleotides comprise one or more nucleosides comprising a modified nucleobase. In certain embodiments, modified oligonucleotides comprise one or more nucleosides that do not comprise a nucleobase, referred to as an abasic nucleoside.
  • modified nucleobases are selected from: 5-substituted pyrimidines, 6-azapyrimidines, alkyl or alkynyl substituted pyrimidines, alkyl substituted purines, and N-2, N-6 and O-6 substituted purines.
  • nucleobases include tricyclic pyrimidines, such as l,3-diazaphenoxazine-2-one, l,3-diazaphenothiazine-2-one, and 9-(2-aminoethoxy)-l,3-diazaphenoxazine-2-one (G-clamp).
  • Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example, 7-deaza- adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone.
  • nucleobases include those disclosed in U.S. Patent No. 3,687,808; Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-VCH, 2008; The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859; Kroschwitz, J.L., Ed., John Wiley & Sons, 1990, 858-859; Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613; Sanghvi, Y.S., Chapter 15, dsRNA Research and Applications, pages 289- 302; Antisense Research and Applications, Crooke, S.T.
  • oligonucleotides comprise modified and/or unmodified nucleobases arranged along the oligonucleotide or region thereof in a defined pattern or motif.
  • each nucleobase is modified.
  • none of the nucleobases are modified.
  • each purine or each pyrimidine is modified.
  • each adenine is modified.
  • each guanine is modified.
  • each thymine is modified.
  • each uracil is modified.
  • each cytosine is modified.
  • some or all of the cytosine nucleobases in a modified oligonucleotide are 5-methylcytosines.
  • modified oligonucleotides comprise a block of modified nucleobases.
  • the block is at the 3 '-end of the oligonucleotide.
  • the block is within 3 nucleosides of the 3 '-end of the oligonucleotide.
  • the block is at the 5 '-end of the oligonucleotide.
  • the block is within 3 nucleosides of the 5 '-end of the oligonucleotide.
  • a 3' to 5' phosphodiester linkage is the naturally occurring intemucleoside linkage of RNA and DNA.
  • an oligonucleotide has one or more modified, z.e., non- naturally occurring, internucleoside linkages.
  • Certain non-naturally occurring intemucleoside linkages may impart desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and increased stability in the presence of nucleases.
  • Methods of preparation of phosphorous -containing and non-phosphorous -containing intemucleoside linkages are well known to those skilled in the art.
  • Further neutral intemucleoside linkages include nonionic linkages comprising siloxane (dialkylsiloxane), carboxylate ester, carboxamide, sulfide, sulfonate ester and amides (See, for example: Carbohydrate Modifications in Antisense Research; Y.S. Sanghvi and P.D. Cook, Eds., ACS Symposium Series 580; Chapters 3 and 4, 40-65). Further neutral intemucleoside linkages include nonionic linkages comprising mixed N, O, S and CH2 component parts.
  • an oligonucleotide comprises at least one modified intemucleoside linkage.
  • a modified intemucleoside linkage may be placed at any position of an oligonucleotide.
  • a modified intemucleoside linkage may be placed within the sense oligonucleotide, antisense oligonucleotide, or both oligonucleotides of the double-stranded compound.
  • the internucleoside linkage modification may occur on every nucleoside of an oligonucleotide. In certain embodiments, internucleoside linkage modifications may occur in an alternating pattern along an oligonucleotide.
  • each internucleoside linking group of a modified oligonucleotide is independently selected from a phosphorothioate and phosphate intemucleoside linkage.
  • the pattern of the intemucleoside linkage modification on each oligonucleotide of a double-stranded compound is the same.
  • the pattern of the intemucleoside linkage modification on each oligonucleotide of a double-stranded compound is different.
  • a double- stranded compound comprises 6-8 modified internucleoside linkages.
  • the 6-8 modified intemucleoside linkages are phosphorothioate intemucleoside linkages or alkylphosphonate intemucleoside linkages.
  • the sense oligonucleotide comprises at least two modified intemucleoside linkages at either or both the 5 '-end and the 3 '-end.
  • the modified intemucleoside linkages are phosphorothioate intemucleoside linkages or alkylphosphonate intemucleoside linkages.
  • the antisense oligonucleotide comprises at least two modified intemucleoside linkages at either or both the 5'- end and the 3 '-end.
  • the modified intemucleoside linkages are phosphorothioate intemucleoside linkages or alkylphosphonate intemucleoside linkages.
  • a double- stranded compound comprises an overhang region.
  • a double- stranded compound comprises a phosphorothioate or alkylphosphonate intemucleoside linkage modification in the overhang region.
  • a double-stranded compound comprises a phosphorothioate or alkylphosphonate intemucleotide linkage linking the overhang nucleotide with a paired nucleotide that is next to the overhang nucleotide.
  • terminal three nucleosides there may be at least two phosphorothioate intemucleoside linkages between the terminal three nucleosides, in which two of the three nucleosides are overhang nucleosides, and the third is a paired nucleoside next to the overhang nucleoside.
  • These terminal three nucleosides may be at the 3 '-end of the antisense oligonucleotide, the 3 '-end of the sense oligonucleotide, the 5 '-end of the antisense oligonucleotide, or the 5 '-end of the antisense oligonucleotide.
  • modified oligonucleotides comprise one or more internucleoside linkages having chiral centers.
  • Representative chiral internucleoside linkages include, but are not limited to, alkylphosphonates and phosphorothioates.
  • Modified oligonucleotides comprising intemucleoside linkages having chiral centers can be prepared as populations of modified oligonucleotides comprising stereorandom internucleoside linkages, or as populations of modified oligonucleotides comprising phosphorothioate linkages in particular stereochemical configurations.
  • populations of modified oligonucleotides comprise phosphorothioate internucleoside linkages wherein all of the phosphorothioate intemucleoside linkages are stereorandom.
  • modified oligonucleotides can be generated using synthetic methods that result in random selection of the stereochemical configuration of each phosphorothioate linkage.
  • each individual phosphorothioate of each individual oligonucleotide molecule has a defined stereoconfiguration.
  • populations of modified oligonucleotides are enriched for modified oligonucleotides comprising one or more particular phosphorothioate intemucleoside linkages in a particular, independently selected stereochemical configuration.
  • the particular configuration of the particular phosphorothioate linkage is present in at least 65% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 70% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 80% of the molecules in the population.
  • the particular configuration of the particular phosphorothioate linkage is present in at least 90% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 99% of the molecules in the population.
  • Such enriched populations of modified oligonucleotides can be generated using synthetic methods known in the art, e.g., methods described in Oka et al., JACS 125, 8307 (2003), Wan et al. Nuc. Acid. Res. 42, 13456 (2014), and WO 2017/015555.
  • a population of modified oligonucleotides is enriched for modified oligonucleotides having at least one indicated phosphorothioate in the (Sp) configuration. In certain embodiments, a population of modified oligonucleotides is enriched for modified oligonucleotides having at least one phosphorothioate in the (Rp) configuration. TrkB Ligands
  • the compounds provided herein comprise a tropomyosin receptor kinase B (TrkB, also known as tyrosine receptor kinase B) ligand.
  • TrkB tropomyosin receptor kinase B
  • a TrkB ligand is useful for directing a therapeutic, prophylactic, or diagnostic agent.
  • a therapeutic agent is an oligonucleotide (e.g., a therapeutic oligonucleotide).
  • a TrkB ligand directs an oligonucleotide to a locality.
  • a TrkB ligand targets tissues.
  • the tissue is brain tissue.
  • a TrkB ligand targets a cell receptor.
  • a cell receptor is TrkB.
  • a TrkB receptor is in the brain.
  • a TrkB receptor is in the frontal cortex.
  • a TrkB receptor is in the striatum.
  • a TrkB receptor is in the cerebellum.
  • a TrkB receptor is in the brain stem.
  • a TrkB receptor is in the hippocampus.
  • a TrkB receptor is in the spinal cord.
  • TrkB ligands are known in the art, and a person of ordinary skill in the art would be capable of identifying additional TrkB ligands for use in the compounds described herein beyond those explicitly provided by the present disclosure.
  • the present disclosure also contemplates the use of derivatives of any TrkB ligand provided herein or known in the art in the presently described compounds, and a person of ordinary skill in the art would know how to make such derivatives.
  • a TrkB ligand is a TrkB agonist. In some embodiments, a TrkB ligand is a TrkB antagonist.
  • Exemplary TrkB ligands for use in the present disclosure include, but are not limited to, any of the following TrkB ligands, and derivatives thereof:
  • a TrkB ligand is an aptamer.
  • aptamers that are TrkB agonists are described in Huang, Y. Z. et al. RNA Aptamer-Based Functional Ligands of the Neurotrophin Receptor, TrkB. Mol. Pharmacol. 2012, 82(4), 623-635.
  • a TrkB ligand is a flavone, a tropoflavin, or a prodrug or derivative thereof.
  • a TrkB ligand is ANA-12. In some embodiments, a TrkB ligand is an anti-TrkB antibody. In certain embodiments, a TrkB ligand is an anti-TrkB antibody fragment, or an anti-TrkB antibody variant.
  • An “anti-TrkB antibody” refers to an immune system protein that recognizes, binds to, or otherwise interacts with a TrkB receptor.
  • a TrkB ligand is conjugated (e.g., linked, connected, attached, associated with) to and agent moiety.
  • the agent moiety is a therapeutic, prophylactic, diagnostic, or imaging agent.
  • the agent is a small molecule or oligomeric compound.
  • the agent moiety is protein, peptide, antibody, oligonucleotide, small molecule, large molecule, or combination thereof.
  • TrkB ligand is conjugated to an agent moiety.
  • at least two TrkB ligands are conjugated to an agent moiety.
  • two TrkB ligands are conjugated to an agent moiety.
  • three TrkB ligands are conjugated to an agent moiety.
  • four TrkB ligands are conjugated to an agent moiety.
  • five TrkB ligands are conjugated to an agent moiety.
  • more than five TrkB ligands are conjugated to an agent moiety.
  • At least one to about five TrkB ligands are conjugated to an agent moiety. In some embodiments, at least one to about four TrkB ligands are conjugated to an agent moiety. In some embodiments, at least one to about three TrkB ligands are conjugated to an agent moiety. In some embodiments, at least one to about two TrkB ligands are conjugated to an agent moiety.
  • TrkB ligands When an agent moiety is conjugated to multiple TrkB ligands, all of the TrkB ligands may be conjugated at or near the same position on the agent moiety, or the TrkB ligands may be conjugated to multiple different positions on the agent moiety.
  • an oligonucleotide is conjugated (e.g., connected, attached, associated with) to a TrkB ligand through either a 5' end and/or a 3' end of the oligonucleotide, or at an internal position in an oligonucleotide (z.e., at a nucleotide on the oligonucleotide other than the 5' or 3' nucleotide).
  • an oligonucleotide is conjugated to a TrkB ligand through the 5' end of the oligonucleotide.
  • an oligonucleotide is conjugated to a TrkB ligand through the 3' end of the oligonucleotide. In some embodiments, an oligonucleotide is conjugated to TrkB ligands through both the 5' end and the 3' end of the oligonucleotide. In some embodiments, an oligonucleotide is conjugated to a TrkB ligand at an internal position within the oligonucleotide (e.g., in an “internally-modified oligonucleotide”). [0273] In some embodiments, an oligonucleotide is conjugated to more than one TrkB ligand.
  • an oligonucleotide is conjugated to at least two TrkB ligands (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more TrkB ligands). In some embodiments, an oligonucleotide is conjugated to two TrkB ligands. In some embodiments, an oligonucleotide is conjugated to three TrkB ligands. In some embodiments, an oligonucleotide is conjugated four TrkB ligands. In some embodiments, an oligonucleotide is conjugated to five TrkB ligands. In some embodiments, an oligonucleotide is conjugated to more than five TrkB ligands.
  • TrkB ligands e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more TrkB ligands.
  • an oligonucleotide is conjugated to at least one to about five TrkB ligands. In some embodiments, an oligonucleotide is conjugated to at least one to about four TrkB ligands. In some embodiments, an oligonucleotide is conjugated to at least one to about three TrkB ligands. In some embodiments, an oligonucleotide is conjugated to at least one to about two TrkB ligands.
  • TrkB ligands When an oligonucleotide is conjugated to multiple TrkB ligands, all of the TrkB ligands may be conjugated at or near the same position on the oligonucleotide, or the TrkB ligands may be conjugated to multiple different positions on the oligonucleotide. In some embodiments, multiple TrkB ligands (z.e., two, three, four, five, or more TrkB ligands) are conjugated at the 5' end of the oligonucleotide.
  • multiple TrkB ligands are conjugated at the 3' end of the oligonucleotide. In some embodiments, multiple TrkB ligands (z.e., two, three, four, five, or more TrkB ligands) are conjugated at one or more internal positions of the oligonucleotide.
  • an oligonucleotide is conjugated to one or more TrkB ligands at the 5' end of the oligonucleotide and/or one or more TrkB ligands at the 3' end of the oligonucleotide and/or one or more TrkB ligands at an internal position, or multiple internal positions, of the oligonucleotide.
  • conjugates of the compound formulae described herein are provided.
  • the conjugates comprise a TrkB ligand covalently coupled to an agent moiety.
  • the conjugates provided herein comprise one or more linker moieties.
  • the one or more linker moieties link a TrkB ligand to an agent moiety.
  • the agent moiety is a protein, peptide, antibody, nucleic acid, small molecule, large molecule, therapeutic, prophylactic, diagnostic, or imaging agent.
  • a compound is conjugated to an oligonucleotide.
  • a TrkB ligand is conjugated to an oligonucleotide.
  • a compound comprises one or more TrkB ligands, one or more linker moieties, and one or more agent moieties, wherein the TrkB ligands are conjugated (e.g., linked, connected, attached, associated with) to the one of more agent moieties through one or more linker moieties.
  • Conjugates as disclosed herein can be manufactured using any available method.
  • agent moieties e.g., a TrkB ligand with an oligonucleotide
  • the moieties may be linked directly or indirectly (e.g., through a linker moiety; that is, the linker is covalently bonded to each of the oligonucleotide and the TrkB ligand; in some formulae herein “-Ln-” wherein n is a number (e.g., Li, L2, L3, and L4).
  • the oligonucleotide and TrkB ligand may be directly associated with one another, e.g., by one or more covalent bonds, or may be associated by means of one or more linkers.
  • a “linker” refers to any chemical moiety (e.g., a combination of atoms having appropriate valency according to known chemistry principles) used to conjugate two components of the compounds provided herein (e.g., a TrkB ligand and an oligonucleotide) to one another. Each of the two components may be connected to any portion of any of the linkers provided herein.
  • one component of the compounds provided herein is connected by a bond to one end of a linker, and the other component is connected by a bond to the other end of the linker.
  • one or both components of the compounds provided herein may be connected by a bond to an internal position within any of the linkers described herein.
  • a TrkB ligand may be joined by a bond to a carbon at one end of the alkyl linker, and an oligonucleotide may be joined by a bond to a carbon at the other end of the alkyl linker.
  • a linker is optionally substituted, and a TrkB ligand or another linker may be joined by a bond to the optional substituent.
  • the compounds provided herein comprise one or more linking groups.
  • each of Li, L2, L3, and L4 comprises a linking group.
  • a linking group is covalently bound to a TrkB ligand.
  • a linking group is covalently bound to an oligonucleotide.
  • a linking group is covalently bound to a cleavable moiety.
  • a linking group comprises a cleavable bond.
  • a linking group does not comprise a cleavable moiety.
  • a linking group comprises a covalent attachment to a solid support.
  • a linking group includes multiple positions for attachment of TrkB ligands.
  • a linking group comprises a chain structure, such as a hydrocarbyl chain, or an oligomer of repeating units or combination of such repeating units.
  • a linking group comprises 1 to 50 repeating units, 1 to 40 repeating units, 1 to 25 repeating units, 1 to 20 repeating units, 1 to 15 repeating units, 1 to 10 repeating units, or 1 to 5 repeating units.
  • a linking group is 1 to 50 atoms long, 1 to 40 atoms long, 1 to 25 atoms long, 1 to 20 atoms long, 1 to 15 atoms long, 1 to 10 atoms long, or 1 to 5 atoms long.
  • a linking group contains carbon atoms. In certain embodiments, a linking group contains heteroatoms (e.g., nitrogen, oxygen, sulfur, etc.). In certain embodiments, a linking group forms amide linkages, ester linkages, or disulfide linkages. In certain embodiments, a linking group forms hydrazone linkages, oxime linkages, imine linkages, guanidine linkages, urea linkages, carbamate linkages, unsaturated alkyl linkages, sulfonamide linkages or 4-8 membered hetero cyclic linkages.
  • a linking group comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino. In certain embodiments, a linking group comprises at least one phosphorus group. In certain embodiments, a linking group comprises at least one phosphate group. In certain embodiments, a linking group includes at least one neutral linking group.
  • a linking group is substituted with various substituents including, but not limited to, hydrogen atoms, alkyl, alkenyl, alkynyl, amino, alkylamino, dialkylamino, trialkylamino, hydroxyl, alkoxy, halogen, aryl, heterocyclic, aromatic heterocyclic, cyano, amide, carbamoyl, carboxylic acid, ester, thioether, alkylthioether, thiol, and ureido groups. As would be appreciated by one of skill in this art, each of these groups may in turn be substituted.
  • a linking group includes, but is not limited to, substituted or unsubstituted Ci-Cio alkyl, substituted or unsubstituted C2-C10 alkenyl, or substituted or unsubstituted C2-C10 alkynyl, wherein a nonlimiting list of preferred substituent groups includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl, and alkynyl.
  • a linking group is an aliphatic or hetero aliphatic.
  • the linking group can a poly alkyl linking group.
  • the linking group can be a polyether linking group.
  • the linking group can be a polyethylene linking group, such as PEG.
  • the linking group is a short peptide chain.
  • a linking group comprises 1 to 40 amino acids, 1 to 25 amino acids, 1 to 20 amino acids, 1 to 15 amino acids, 1 to 10 amino acids, or 1 to 5 amino acids.
  • a linking group comprises linker-nucleosides. In certain embodiments, a linking group comprises 1 to 40 linker-nucleosides, 1 to 25 linker-nucleosides, 1 to 20 linker-nucleosides, 1 to 15 linker-nucleosides, 1 to 10 linker-nucleosides, or 1 to 5 linker- nucleosides. In certain embodiments, such linker-nucleosides may be modified or unmodified nucleosides. It is typically desirable for linker-nucleosides to be cleaved from the compound after it reaches a target tissue.
  • linker-nucleosides herein can be linked to one another and to the remainder of the compound through cleavable bonds.
  • linker-nucleosides are not considered to be part of an oligonucleotide payload.
  • a compound comprises an oligonucleotide consisting of a specified number or range of linked nucleosides and/or a specified percent complementarity to a reference nucleic acid and the compound also comprises a TrkB ligand comprising a linking group comprising linker- nucleosides
  • those linker-nucleosides are not counted toward the length of the oligonucleotide and are not used in determining the percent complementarity of the oligonucleotide for the reference nucleic acid.
  • the linking group includes a protein binding group.
  • the protein binding group is a lipid such as for example including but not limited to cholesterol, cholic acid, adamantane acetic acid, 1 -pyrene butyric acid, dihydrotestosterone, 1,3- Bis- O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3- propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, 03- (oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine), a vitamin (e.g., folate, vitamin A, vitamin E, biotin, pyridoxal), a peptide, a carbohydrate (e.g., monos
  • a linking group includes, but is not limited to, pyrrolidine, 8- amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl) cyclohexane- 1- carboxylate (SMCC) and 6-aminohexanoic acid (AHEX or AHA).
  • ADO 8- amino-3,6-dioxaoctanoic acid
  • SMCC succinimidyl 4-(N-maleimidomethyl) cyclohexane- 1- carboxylate
  • AHEX or AHA 6-aminohexanoic acid
  • a linking group includes, without limitation, those linking groups described in the following references: US 5,994,517; US 6,300,319; US 6,660,720; US 6,906,182; US 7,262,177; US 7,491,805; US 8,106,022; US 7,723,509; US 9,127,276; US 2006/0148740;
  • Li, L2, L3, and L4 independently comprise or together comprise a structure selected from among:
  • Li, L2, L3, and L4 independently comprise or together comprise the structure selected from among:
  • n is, independently, from 1 to 20.
  • Li, L2, L3, and L4 independently comprise or together comprise the structure selected from among:
  • Li, L2, L3, and L4 independently comprise or together comprise the structure selected from among: , wherein each L is, independently, a phosphorous linking group; and each n is, independently, from 1 to 20.
  • Li, L2, L3, and L4 independently comprise or together comprise the structure selected from among:
  • Li, L2, L3, and L4 independently comprise or together comprise the structure selected from among:
  • Li, L2, L3, and L4 independently comprise or together comprise the structure selected from among:
  • Li, L2, L3, and L4 independently comprise or together comprise the structure selected from among:
  • Li, L2, L3, and L4 independently comprise or together comprise the structure selected from among:
  • Li, L2, L3, and L4 independently comprise or together comprise the structure selected from among: [0296] In certain embodiments, Li, L2, L3, and L4 independently comprise or together comprise the structure selected from among:
  • Li, L2, L3, and L4 independently comprise or together have the structure:
  • Li, L2, L3, and L4 independently comprise or together have the structure:
  • Li, L2, L3, and L4 independently comprise or together comprise the structure selected from among:
  • Li, L2, L3, and L4 independently comprise or together comprise the structure selected from among: wherein each n is independently
  • each of Li, L2, L3, and L4 is independently absent, a bond, an optionally substituted alkyl linker, an optionally substituted polyethylene glycol (PEG) linker, an optionally substituted heteroalkyl linker (e.g., a C1-20 alkyl linker in which any one or more carbon atoms is replaced with a heteroatom, such as N, O, P, or S), or an optionally substituted heteroaryl linker.
  • Li is an optionally substituted heteroaryl linker.
  • Li is an optionally substituted unsaturated heteroaryl linker.
  • Li comprises the structure some embodiments, Li is an optionally substituted heteroalkyl linker.
  • Li comprises the structure . In certain embodiments, Li comprises the structure or -N(CH 3 ) -.
  • L2 is an optionally substituted PEG linker. In some embodiments, the PEG linker is five PEG units in length. In some embodiments, the PEG linker is four PEG units in length. In some embodiments, the PEG linker is three PEG units in length. In some embodiments, L2 is an optionally substituted alkyl linker. In some embodiments, L2 is an optionally substituted Ci-20 alkyl linker. In certain embodiments, L2 is an optionally substituted Cs alkyl linker.
  • L3 is an optionally substituted heteroaryl linker. In some embodiments, L3 is an optionally substituted partially unsaturated heteroaryl linker. In certain embodiments,
  • L4 is an optionally substituted heteroalkyl linker.
  • the heteroalkyl linker comprises two substituents joined together to form an optionally substituted carbocyclyl ring.
  • L4 comprises the structure , wherein X is O or S. In certain embodiments, L4 comprises the structure wherein X is O or S.
  • Li, L2, L3, and L4 together comprise the structure wherein X is O or S. In some embodiments, Li, L2, L3, and L4 together comprise the structure wherein X is O or S. In some embodiments, Li, L2, L3, and L4 together comprise the structure
  • Li, L2, L3, and L4 together comprise the structure wherein X is O or S. In some embodiments, Li, L2, L3, and L4 together comprise the structure wherein X is O or S. In some embodiments, Li, L2, L3, and L4 together comprise the structure wherein X is O or S.
  • the disclosure relates to methods of making the compounds and compositions comprising TrkB ligands as disclosed herein.
  • the compounds herein may also contain linkages (e.g., carbon-carbon bonds) wherein bond rotation is restricted about that particular linkage, e.g., restriction resulting from the presence of a ring or double bond. Accordingly, all cis/trans and E/Z isomers are expressly included in the present disclosure.
  • the compounds herein may also be represented in multiple tautomeric forms; in such instances, the present disclosure expressly includes all tautomeric forms of the compounds described herein, even though only a single tautomeric form may be represented. All such isomeric forms of such compounds herein are expressly included in the present disclosure. All crystal forms and polymorphs of the compounds described herein are expressly included in the present disclosure.
  • extracts and fractions comprising compounds of the present disclosure.
  • the term “isomers” is intended to include diastereoisomers, enantiomers, regioisomers, structural isomers, rotational isomers, tautomers, and the like.
  • the methods of the present disclosure may be carried out with an enantiomerically enriched compound, a racemate, or a mixture of diastereomers. All isomers of compounds delineated herein are expressly included in the present disclosure.
  • Preferred enantiomerically enriched compounds have an enantiomeric excess of 50% or more. More preferably, the compound has an enantiomeric excess of 60%, 70%, 80%, 90%, 95%, 98%, 99%, or more. In preferred embodiments, only one enantiomer or diastereomer of a chiral compound of the present disclosure is administered to cells or a subject.
  • kits for treating a subject suffering from or susceptible to a disorder or disease comprising administering to the subject an effective amount of a compound or pharmaceutical composition described herein.
  • kits for treating a subject suffering from or susceptible to a disorder or disease, wherein the subject has been identified as in need of modulation of the function of a protein comprising administering to said subject in need thereof, an effective amount of a compound or pharmaceutical composition described herein, such that said subject is treated for said disorder.
  • a therapeutic oligonucleotide to the brain of a subject, comprising contacting the subject with a compound or pharmaceutical composition described herein, in an amount and under conditions sufficient to target the brain.
  • the therapeutic oligonucleotide is delivered to one or more brain regions selected from the group consisting of the striatum, the cerebellum, the brain stem, the hippocampus, the frontal cortex, and the spinal cord.
  • the disease is a neurodegenerative disease, disorder, or symptom thereof.
  • the disease is Alzheimer’s disease, or a symptom thereof.
  • Exemplary CNS disorders include, but are not limited to, neurotoxicity and/or neurotrauma, stroke, multiple sclerosis, spinal cord injury, epilepsy, a mental disorder, a sleep condition, a movement disorder, nausea and/or emesis, amyotrophic lateral sclerosis, Alzheimer’s disease, and drug addiction.
  • the CNS disorder is neurotoxicity and/or neurotrauma, e.g., for example, as a result of acute neuronal injury (e.g., traumatic brain injury (TBI), stroke, epilepsy) or a chronic neurodegenerative disorder (e.g., multiple sclerosis, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, Alzheimer’s disease).
  • acute neuronal injury e.g., traumatic brain injury (TBI), stroke, epilepsy
  • a chronic neurodegenerative disorder e.g., multiple sclerosis, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, Alzheimer’s disease.
  • the compounds of the present disclosure provide a neuroprotective effect, e.g., against an acute neuronal injury or a chronic neurodegenerative disorder.
  • the CNS disorder is stroke (e.g., ischemic stroke).
  • the CNS disorder is multiple sclerosis.
  • the CNS disorder is spinal cord injury.
  • the CNS disorder is epilepsy.
  • the CNS disorder is a mental disorder, e.g., for example, depression, anxiety or anxiety-related conditions, a learning disability, somatic symptom disorder, or schizophrenia or schizoaffective disorder.
  • a mental disorder e.g., for example, depression, anxiety or anxiety-related conditions, a learning disability, somatic symptom disorder, or schizophrenia or schizoaffective disorder.
  • the CNS disorder is depression.
  • “Depression” includes, but is not limited to, depressive disorders or conditions, such as, for example, major depressive disorders (e.g., unipolar depression), treatment-resistant depression, dysthymic disorders (e.g., chronic, mild depression), bipolar disorders (e.g., manic depression), seasonal affective disorder, and/or depression associated with substance abuse or substance abuse disorder (e.g., withdrawal).
  • the depression can be clinical or subclinical depression.
  • the depression can be associated with or premenstrual syndrome and/or premenstrual dysphoric disorder.
  • the CNS disorder is anxiety.
  • “Anxiety” includes, but is not limited to, anxiety and anxiety-related conditions, such as, for example, clinical anxiety, panic disorder, agoraphobia, generalized anxiety disorder (GAD), specific phobia, social phobia, obsessive-compulsive disorder, acute stress disorder, post-traumatic stress disorder, adjustment disorders with anxious features, anxiety disorder associated with depression, anxiety disorder due to general medical conditions, and substance-induced anxiety disorders, anxiety associated with substance abuse or substance use disorder (e.g., withdrawal, dependence, reinstatement) and anxiety associated with nausea and/or emesis.
  • This treatment may also be to induce or promote sleep in a subject (e.g., for example, a subject with anxiety).
  • the CNS disorder is a learning disorder (e.g., attention deficit disorder (ADD)).
  • ADD attention deficit disorder
  • the CNS disorder is schizophrenia or schizoaffective disorder.
  • the CNS disorder is a sleep condition.
  • sleep conditions include, but are not limited to, insomnia, narcolepsy, sleep apnea, restless legs syndrome (RLS), delayed sleep phase syndrome (DSPS), periodic limb movement disorder (PLMD), hypopnea syndrome, rapid eye movement behavior disorder (RBD), shift work sleep condition (SWSD), and sleep problems (e.g., parasomnias) such as nightmares, night terrors, sleep talking, head banging, snoring, and clenched jaw and/or grinding of teeth (bruxism).
  • the CNS disorder is a movement disorder, e.g., basal ganglia disorders, such as, for example, Parkinson’s disease, levodopa-induced dyskinesia, Huntington’s disease, Gilles de la Tourette’s syndrome, tardive dyskinesia, and dystonia.
  • basal ganglia disorders such as, for example, Parkinson’s disease, levodopa-induced dyskinesia, Huntington’s disease, Gilles de la Tourette’s syndrome, tardive dyskinesia, and dystonia.
  • the CNS disorder is Alzheimer’s disease.
  • the CNS disorder is amyotrophic lateral sclerosis (ALS).
  • ALS amyotrophic lateral sclerosis
  • the CNS disorder is nausea and/or emesis.
  • the CNS disorder is drug addiction (e.g., for instance, addiction to opiates, nicotine, cocaine, psychostimulants, or alcohol).
  • drug addiction e.g., for instance, addiction to opiates, nicotine, cocaine, psychostimulants, or alcohol.
  • neurodegenerative diseases refers to any disease of the nervous system, including diseases that involve the central nervous system (brain, brainstem, and cerebellum), the peripheral nervous system (including cranial nerves), and the autonomic nervous system (parts of which are located in both central and peripheral nervous system).
  • Neurodegenerative diseases refer to a type of neurological disease marked by the loss of nerve cells, including, but not limited to, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, tauopathies (including frontotemporal dementia), and Huntington’s disease.
  • neurological diseases include, but are not limited to, headache, stupor and coma, dementia, seizure, sleep disorders, trauma, infections, neoplasms, neuro-ophthalmology, movement disorders, demyelinating diseases, spinal cord disorders, and disorders of peripheral nerves, muscle, and neuromuscular junctions.
  • Substance abuse or substance use disorder (SUD) and mental illness including, but not limited to, bipolar disorder, schizophrenia, and schizoaffective disorder, are also included in the definition of neurological diseases.
  • neurological diseases include acquired epileptiform aphasia; acute disseminated encephalomyelitis; adrenoleukodystrophy; agenesis of the corpus callosum; agnosia; Aicardi syndrome; Alexander disease; Alpers’ disease; alternating hemiplegia; Alzheimer’s disease; amyotrophic lateral sclerosis; anencephaly; Angelman syndrome; angiomatosis; anoxia; aphasia; apraxia; arachnoid cysts; arachnoiditis; Arnold-Chiari malformation; arteriovenous malformation; Asperger syndrome; ataxia telangiectasia; attention deficit hyperactivity disorder; autism; autonomic dysfunction; back pain; Batten disease; Behcet’s disease; Bell’s palsy; benign essential blepharospasm; benign focal; amyotrophy; benign intracranial hypertension; Binswanger’s disease; blepharospasm; Bloch
  • the subject is a mammal, preferably a primate or a human.
  • kits as described above, wherein the compounds provided herein is administered intrathecally, intravenously, intramuscularly, subcutaneously, intracerebroventricularly, orally, or topically. In certain embodiments, the compound is administered intrathecally.
  • kits as described above, wherein the compound of any of the formulae provided herein is administered alone or in combination with one or more other therapeutics.
  • the additional therapeutic agent is a central nervous system (CNS) disease agent.
  • CNS central nervous system
  • Another object of the present disclosure is the use of a compound as described herein in the manufacture of a medicament for use in the treatment of a disorder or disease.
  • Another object of the present disclosure is the use of a compound as described herein for use in the treatment of a disorder or disease.
  • compositions comprising any of the compounds described herein and a pharmaceutically acceptable carrier or pharmaceutically acceptable excipient.
  • a compound or composition, as described herein, can be administered in combination with one or more additional therapeutic agents (e.g., therapeutically and/or prophylactically active agents).
  • the compounds or compositions can be administered in combination with additional therapeutic agents that improve their activity (e.g., activity (e.g., potency and/or efficacy) in treating a disease in a subject in need thereof, in preventing a disease in a subject in need thereof, and/or in reducing the risk to develop a disease in a subject in need thereof), improve bioavailability, improve safety, reduce drug resistance, reduce and/or modify metabolism, inhibit excretion, and/or modify distribution in a subject or cell.
  • additional therapeutic agents e.g., therapeutically and/or prophylactically active agents.
  • additional therapeutic agents that improve their activity (e.g., activity (e.g., potency and/or efficacy) in treating a disease in a subject in need thereof, in preventing a disease in a subject in need thereof, and/or in reducing
  • a pharmaceutical composition described herein including a compound described herein and an additional therapeutic agent exhibits a synergistic effect that is absent in a pharmaceutical composition including one of the compounds described herein or the additional therapeutic agent, but not both.
  • the compound or composition can be administered concurrently with, prior to, or subsequent to one or more additional therapeutic agents, which may be useful as, e.g., combination therapies.
  • Therapeutic agents include therapeutically active agents.
  • Therapeutic agents also include prophylactically active agents.
  • Therapeutic agents include small organic molecules such as drug compounds (e.g., compounds approved for human or veterinary use by the U.S.
  • the additional therapeutic agent is a therapeutic agent useful for treating and/or preventing a disease (e.g., CNS disorder).
  • Each additional therapeutic agent may be administered at a dose and/or on a time schedule determined for that therapeutic agent.
  • the additional therapeutic agents may also be administered together with each other and/or with the compound or composition described herein in a single dose or administered separately in different doses.
  • the particular combination to employ in a regimen will take into account compatibility of the compound described herein with the additional therapeutic agent(s) and/or the desired therapeutic and/or prophylactic effect to be achieved.
  • the additional therapeutic agent(s) in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
  • kits comprising an effective amount of a compound provided herein, in unit dosage form, together with instructions for administering the compound to a subject suffering from or susceptible to a disease or disorder.
  • pharmaceutically acceptable salts or “pharmaceutically acceptable carrier” is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
  • base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
  • pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
  • acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
  • pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydroiodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
  • salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, e.g., Berge et al., Journal of Pharmaceutical Science 66:1-19 (1977)).
  • Certain specific compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
  • Other pharmaceutically acceptable carriers known to those of skill in the art are suitable for the present disclosure.
  • the neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
  • the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present disclosure.
  • the present disclosure provides compounds which are in a prodrug form.
  • Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present disclosure.
  • prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present disclosure when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
  • Certain compounds of the present disclosure can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present disclosure. Certain compounds of the present disclosure may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present disclosure and are intended to be within the scope of the present disclosure.
  • the present disclosure also provides a pharmaceutical composition, comprising an effective amount of a compound described herein and a pharmaceutically acceptable excipient.
  • a compound of any of the formulae provided herein is administered to a subject using a pharmaceutically acceptable formulation, e.g., a pharmaceutically acceptable formulation that provides sustained delivery of the compound to a subject for at least 12 hours, 24 hours, 36 hours, 48 hours, one week, two weeks, three weeks, or four weeks after the pharmaceutically- acceptable formulation is administered to the subject.
  • compositions of the disclosure may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular subject, composition, and mode of administration, while being acceptably tolerant to the subject.
  • at least one compound according to the present disclosure is administered in a pharmaceutically effective amount to a subject in need thereof in a pharmaceutical carrier by intravenous, intrathecal, intramuscular, subcutaneous, or intracerebroventricular injection (ICV) or by oral administration or topical application.
  • a compound of the disclosure may be administered alone or in conjunction with a second, different therapeutic. By “in conjunction with” is meant together, substantially simultaneously, or sequentially.
  • a compound of the disclosure is administered acutely.
  • the compound of the disclosure may therefore be administered for a short course of treatment, such as for about 1 day to about 1 week.
  • the compound of the disclosure may be administered over a longer period of time to ameliorate chronic disorders, such as, for example, for about one week to several months depending upon the condition to be treated.
  • pharmaceutically effective amount is meant an amount of a compound of the disclosure, high enough to significantly positively modify the condition to be treated but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment.
  • a pharmaceutically effective amount of a compound of the disclosure will vary with the particular goal to be achieved, the age and physical condition of the patient being treated, the severity of the underlying disease, the duration of treatment, the nature of concurrent therapy and the specific compound employed. For example, a therapeutically effective amount of a compound of the disclosure administered to a child or a neonate will be reduced proportionately in accordance with sound medical judgment. The effective amount of a compound of the disclosure will thus be the minimum amount which will provide the desired effect.
  • a decided practical advantage of the present disclosure is that the compound may be administered in a convenient manner such as by intrathecal, intravenous, intramuscular, subcutaneous, oral, or intra-cerebroventricular injection routes or by topical application, such as in creams or gels.
  • the active ingredients which comprise a compound of the disclosure may be required to be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.
  • the compound can be coated by, or administered with, a material to prevent inactivation.
  • the compound may be administered parenterally or intraperitoneally.
  • Dispersions can also be prepared, for example, in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils.
  • substances which can serve as pharmaceutical excipients, or pharmaceutical carriers are sugars, such as lactose, glucose and sucrose; starches such as com starch and potato starch; cellulose and its derivatives such as sodium carboxymethycellulose, ethylcellulose and cellulose acetates; powdered tragancanth; malt; gelatin; talc; stearic acids; magnesium stearate; calcium sulfate; vegetable oils, such as peanut oils, cotton seed oil, sesame oil, olive oil, com oil, and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; agar; alginic acids; pyrogen-free water; isotonic saline; and phosphate buffer solution; skim milk powder; as well as other non-toxic compatible substances used in pharmaceutical formulations such as Vitamin C, estrogen
  • wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, lubricants, excipients, tableting agents, stabilizers, antioxidants, and preservatives, can also be present.
  • Solubilizing agents including for example, cremaphore, and beta-cyclodextrins, can also be used in the pharmaceutical compositions herein.
  • compositions comprising the active compounds of the present disclosure (or prodmgs thereof) can be manufactured by means of conventional mixing, dissolving, granulating, dragee-making levigating, emulsifying, encapsulating, entrapping, or lyophilization processes.
  • the compositions can be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients, or auxiliaries, which facilitate processing of the active compounds into preparations that can be used pharmaceutically.
  • compositions herein can be made by combining (e.g., contacting, mixing, dissolving, granulating, drageemaking, levigating, emulsifying, encapsulating, entrapping, or lyophilizing) a compound delineated herein with one or more suitable carriers, diluents, excipients, or auxiliaries, including those described herein (e.g., for pharmaceutical, agricultural, or veterinary use).
  • compositions of the present disclosure can take a form suitable for virtually any mode of administration, including, for example, intrathecal, topical, ocular, oral, buccal, systemic, nasal, injection, transdermal, rectal, vaginal, and the like, or a form suitable for administration by inhalation or insufflation.
  • Systemic formulations include those designed for administration by injection, e.g., subcutaneous, intravenous, intramuscular, intrathecal, or intraperitoneal injection, as well as those designed for transdermal, transmucosal, oral, or pulmonary administration.
  • Useful injectable preparations include sterile suspensions, solutions, or emulsions of the active compound(s) in aqueous or oily vehicles.
  • the compositions also can contain formulating agents, such as suspending, stabilizing and/or dispersing agent.
  • the formulations for injection can be presented in unit dosage form (e.g., in ampules or in multidose containers) and can contain added preservatives.
  • the injectable formulation can be provided in powder form for reconstitution with a suitable vehicle, including but not limited to, sterile pyrogen free water, buffer, dextrose solution, and the like, before use.
  • a suitable vehicle including but not limited to, sterile pyrogen free water, buffer, dextrose solution, and the like.
  • the active compound(s) can be dried by any art-known technique, such as lyophilization, and reconstituted prior to use.
  • the active compound(s), or prodrug(s) can be formulated as a depot preparation for administration by implantation or intramuscular injection.
  • the active ingredient can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, e.g., as a sparingly soluble salt.
  • Liposomes and emulsions are well-known examples of delivery vehicles that can be used to deliver active compound(s), oligonucleotide(s), or prodrug(s).
  • Certain organic solvents such as dimethylsulfoxide (DMSO) also can be employed.
  • compositions can, if desired, be presented in a pack or dispenser device that can contain one or more unit dosage forms containing the active compound(s).
  • the pack can, for example, comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device can be accompanied by instructions for administration.
  • the active compound(s), or prodrug(s) of the present disclosure, or compositions thereof, will generally be used in an amount effective to achieve the intended result, for example in an amount effective to treat or prevent the particular disease being treated.
  • the compound(s) and oligonucleotide(s) can be administered therapeutically to achieve therapeutic benefit or prophy tactically to achieve prophylactic benefit.
  • therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated and/or eradication or amelioration of one or more of the symptoms associated with the underlying disorder such that the patient reports an improvement in feeling or condition, notwithstanding that the patient can still be afflicted with the underlying disorder.
  • Therapeutic benefit also includes halting or slowing the progression of the disease, regardless of whether improvement is realized.
  • the compound can be administered to a patient at risk of developing one of the previously described diseases.
  • a patient at risk of developing a disease can be a patient having characteristics placing the patient in a designated group of at-risk patients, as defined by an appropriate medical professional or group.
  • a patient at risk may also be a patient that is commonly or routinely in a setting where development of the underlying disease could occur.
  • an at-risk patient is one who is commonly or routinely exposed to the disease or illness causing conditions or may be acutely exposed for a limited time.
  • prophylactic administration can be applied to avoid the onset of symptoms in a patient diagnosed with the underlying disorder.
  • Effective dosages can be estimated initially from in vitro assays. For example, an initial dosage for use in animals can be formulated to achieve a circulating blood or serum concentration of active compound that is at or above an IC50 of the particular compound as measured in an in vitro assay, such as an in vitro fungal MIC or MFC, and other in vitro assays.
  • Dosage amounts will typically be in the range of from about 0.0001 or 0.001 or 0.01 mg/kg/day to about 100 mg/kg/day, but can be higher or lower, depending upon, among other factors, the activity of the compound, its bioavailability, the mode of administration, and various factors discussed above. Dosage amount and interval can be adjusted individually to provide plasma levels of the compound(s) that are sufficient to maintain therapeutic or prophylactic effect. In cases of local administration or selective uptake, such as local topical administration, the effective local concentration of active compound(s) cannot be related to plasma concentration. Skilled artisans will be able to optimize effective local dosages without undue experimentation.
  • the compound(s) will provide therapeutic or prophylactic benefit and will have acceptable tolerability.
  • Tolerability of the compound(s) and oligonucleotide(s) can be determined using standard pharmaceutical procedures.
  • the dose ratio between non-tolerable and therapeutic (or prophylactic) effect is the therapeutic index.
  • Compounds(s) that exhibit high therapeutic indices are preferred.
  • Embodiment Pl A compound comprising the structure of Formula (I), or a salt thereof:
  • Formula (I) wherein is a Tropomyosin receptor B (TrkB) ligand; each of Li, L2, L3, and L4 is independently a linker or absent; and
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide.
  • Embodiment P2 The compound, or salt thereof, of embodiment Pl, wherein the TrkB ligand is a TrkB agonist.
  • Embodiment P3. The compound, or salt thereof, of embodiment Pl or P2, wherein the TrkB ligand is selected from the group consisting of 3,7-dihydroxyflavone, 3, 7,8,2'- tetrahydroxyflavone, 7,3'-dihydroxyflavone, 7,8,2'-trihydroxyflavone, 7,8,3 '-trihydroxyflavone, 7,8,4'-trihydroxyflavone, diosmetin (5,7,3'-trihydroxy-4'-methoxyflavone), 7-hydroxy-4'- methoxyflavone, 8-hydroxy-7-methoxyflavone, eutropoflavin (4'-dimethylamino-7,8- dihydroxy flavone), norwogonin (5,7,8-trihydroxyflavone), R7, R
  • Embodiment P4 The compound, or salt thereof, of any one of embodiments P1-P3, wherein the TrkB ligand is flavone, tropoflavin, or a prodrug or derivative thereof.
  • Embodiment P5. The compound, or salt thereof, of any one of embodiments P1-P4, wherein the compound comprises the structure of Formula (II), or a salt thereof:
  • R 2 is hydrogen, -OH, optionally substituted -O-alkyl, optionally substituted -OAc, -NH2, optionally substituted -NHAc, or -SH;
  • R 3 is hydrogen, -OH, optionally substituted -O-alkyl, optionally substituted -OAc, -NH2, optionally substituted -NHAc, or -SH;
  • R 4 is hydrogen, -OH, optionally substituted -O-alkyl, optionally substituted -OAc, -NH2, optionally substituted -NHAc, or -SH;
  • R 5 is hydrogen, -OH, optionally substituted -O-alkyl, optionally substituted -OAc, -NH2, optionally substituted -NHAc, or -SH;
  • Y is CH 2 , NH, S, or O;
  • Z is optionally substituted aryl or optionally substituted heteroaryl.
  • Embodiment P6 The compound, or salt thereof, of embodiment P5, wherein the compound comprises the structure of Formula (II- a):
  • Embodiment P7 The compound, or salt thereof, of embodiment P5, wherein the compound comprises the structure of Formula (Il-b):
  • Embodiment P8 The compound, or salt thereof, of embodiment P5, wherein the compound comprises the structure of Formula (II-c) :
  • Embodiment P9 The compound, or salt thereof, of any one of embodiments P5-P8, wherein R 2 is -OH.
  • Embodiment PIO The compound, or salt thereof, of any one of embodiments P5-P9, wherein R 3 is -OH.
  • Embodiment Pl l The compound, or salt thereof, of any one of embodiments P5-P10, wherein R 4 is hydrogen.
  • Embodiment P12 The compound, or salt thereof, of any one of embodiments P5-P11, wherein R 5 is hydrogen.
  • Embodiment P14 The compound, or salt thereof, of any one of embodiments P5-P13, wherein Y is O.
  • Embodiment P15 The compound, or salt thereof, of any one of embodiments P5-P14, wherein Z is optionally substituted aryl.
  • Embodiment Pl The compound, or salt thereof, of any one of embodiments P5-P15, wherein Z is optionally substituted phenyl.
  • Embodiment P17 The compound, or salt thereof, of any one of embodiments P5-P16, wherein Z is unsubstituted phenyl.
  • Embodiment P18 The compound, or salt thereof, of any one of embodiments P5-P16, wherein Z is phenyl substituted with one or more -OH and/or -O-alkyl.
  • Embodiment Pl 9. The compound, or salt thereof, of embodiment P5, wherein the compound comprises the structure of Formula (III):
  • Embodiment P20 The compound, or salt thereof, of embodiment Pl 9, wherein the compound comprises the structure of Formula (Ill-a): Formula (III- a) or a salt thereof.
  • Embodiment P21 The compound, or salt thereof, of embodiment Pl 9, wherein the compound comprises the structure of Formula (Ill-b):
  • Embodiment P22 The compound, or salt thereof, of embodiment P19, wherein the compound comprises the structure of Formula (III-c):
  • Embodiment P23 The compound, or salt thereof, of embodiment P22, wherein the compound comprises the structure of Formula (III-c- 1):
  • Embodiment P24 The compound, or salt thereof, of any one of embodiments P1-P3, wherein the TrkB ligand is ANA- 12, or a prodrug or derivative thereof.
  • Embodiment P25 The compound, or salt thereof, of any one of embodiments P1-P3 or P24, wherein the compound comprises the structure of Formula (IV):
  • Embodiment P26 The compound, or salt thereof, of embodiment P25, wherein the compound comprises the structure of Formula (IV-a): or a salt thereof.
  • Embodiment P27 The compound, or salt thereof, of embodiment P25, wherein the compound comprises the structure of Formula (IV-b): or a salt thereof.
  • Embodiment P28 The compound, or salt thereof, of any one of embodiments P1-P27, wherein each of Li, L2, L3, and L4 is independently absent, a bond, an optionally substituted alkyl linker, an optionally substituted polyethylene glycol (PEG) linker, an optionally substituted heteroalkyl linker, or an optionally substituted heteroaryl linker.
  • Embodiment P29 The compound, or salt thereof, of embodiment P28, wherein Li is an optionally substituted heteroaryl linker.
  • Embodiment P30 The compound, or salt thereof, of embodiment P29, wherein Li is an optionally substituted unsaturated heteroaryl linker.
  • Embodiment P31 The compound, or salt thereof, of embodiment P29 or P30, wherein Li comprises the structure
  • Embodiment P32 The compound, or salt thereof, of embodiment P28, wherein Li is an optionally substituted heteroalkyl linker.
  • Embodiment P33 The compound, or salt thereof, of embodiment P32, wherein the optionally substituted heteroalkyl linker is an optionally substituted Ci-Cio alkyl chain in which one or more carbon atoms are replaced with O, N, or S.
  • Embodiment P34 The compound, or salt thereof, of embodiment P32 or P33, wherein Li
  • HN ⁇ comprises the structure .
  • Embodiment P35 The compound, of salt thereof, of embodiment P32 or P33, wherein Li comprises the structure .
  • Embodiment P36 The compound, or salt thereof, of any one of embodiments P28-P35, wherein L2 is an optionally substituted PEG linker.
  • Embodiment P37 The compound, or salt thereof, of embodiment P36, wherein the PEG linker is five PEG units in length.
  • Embodiment P38 The compound, or salt thereof, of embodiment P36, wherein the PEG linker is four PEG units in length.
  • Embodiment P39 The compound, of salt thereof, of embodiment P36, wherein the PEG linker is three PEG units in length.
  • Embodiment P40 The compound, or salt thereof, of any one of embodiments P28-P35, wherein L2 is an optionally substituted alkyl linker.
  • Embodiment P41 The compound, or salt thereof, of embodiment P40, wherein L2 is an optionally substituted Ci-20 alkyl linker.
  • Embodiment P42 The compound, or salt thereof, of embodiment P40 or P41, wherein L2 is an optionally substituted Cs alkyl linker.
  • Embodiment P43 The compound, or salt thereof, of any one of embodiments P28-P42, wherein L3 is an optionally substituted heteroaryl linker.
  • Embodiment P44 The compound, or salt thereof, of embodiment P43, wherein L3 is an optionally substituted partially unsaturated heteroaryl linker.
  • Embodiment P45 The compound, or salt thereof, of embodiment P44, wherein L3 comprises the structure:
  • Embodiment P46 The compound, or salt thereof, of any one of embodiments P28-P45, wherein L4 is an optionally substituted heteroalkyl linker.
  • Embodiment P48 The compound, or salt thereof, of embodiment P46 or P47, wherein the heteroalkyl linker comprises two substituents joined together to form an optionally substituted carbocyclyl ring.
  • Embodiment P49 The compound, or salt thereof, of embodiment P46 or P47, wherein L4 comprises the structure: wherein X is O or S.
  • Embodiment P50 The compound, or salt thereof, of any one of embodiments P46-P48, wherein L4 comprises the structure: wherein X is O or S.
  • Embodiment P51 The compound, or salt thereof, of embodiment P28, wherein Li, L2, L3, and L4 together comprise the structure wherein X is O or S.
  • Embodiment P52 The compound, or salt thereof, of embodiment P28, wherein Li, L2, L3, and L4 together comprise the structure wherein X is O or S.
  • Embodiment P53 The compound, or salt thereof, of embodiment P28, wherein Li, L2, L3, and L4 together comprise the structure: wherein X is O or S.
  • Embodiment P54 The compound, or salt thereof, of embodiment P28, wherein Li, L2, L3, and L4 together comprise the structure wherein X is O or S.
  • Embodiment P55 The compound, or salt thereof, of embodiment P28, wherein Li, L2, L3, and L4 together comprise the structure: wherein X is O or S.
  • Embodiment P56 The compound, or salt thereof, of embodiment P28, wherein Li, L2, L3, and L4 together comprise the structure: , wherein
  • X is O or S.
  • Embodiment P57 The compound, or salt thereof, of any one of embodiments P1-P56, wherein the compound comprises the structure:
  • Embodiment P58 The compound, or salt thereof, of any one of embodiments P1-P56, or a salt thereof, wherein X is O or S.
  • Embodiment P59 The compound, or salt thereof, of any one of embodiments P49-P58, wherein X is O.
  • Embodiment P60 The compound, or salt thereof, of any one of embodiments P49-P58, wherein X is S.
  • Embodiment P61 The compound, or salt thereof, of any one of embodiments P1-P60, wherein R 1 comprises an oligonucleotide.
  • Embodiment P62 The compound, or salt thereof, of embodiment P61, wherein the oligonucleotide is attached at its 5' end.
  • Embodiment P63 The compound, or salt thereof, of embodiment P61, wherein the oligonucleotide is attached at its 3' end.
  • Embodiment P64 The compound, or salt thereof, of embodiment P61, wherein the oligonucleotide is attached at an internal position on the oligonucleotide.
  • Embodiment P65 The compound, or salt thereof, of embodiment P64, wherein the internal position is an intemucleoside linkage.
  • Embodiment P66 The compound, or salt thereof, of any one of embodiments P1-P65, wherein R 1 comprises an oligonucleotide conjugated to one or more additional TrkB ligands.
  • Embodiment P67 The compound, or salt thereof, of embodiment P66, wherein the oligonucleotide is conjugated to two, three, four, five, or more than five additional TrkB ligands.
  • Embodiment P68 Embodiment P68.
  • Embodiment P69 The compound, or salt thereof, of any one of embodiments P61-P68, wherein the oligonucleotide is a modified oligonucleotide.
  • Embodiment P70 A composition comprising a compound, or salt thereof, of any one of embodiments P1-P69, and a pharmaceutically acceptable excipient.
  • Embodiment P71 A method for delivering a therapeutic oligonucleotide to the brain of a subject, comprising administration of a compound, or salt thereof, of any one of embodiments Pl- P69, or a composition of embodiment P70, to the subject.
  • Embodiment P72 The method of embodiment P71, wherein the therapeutic oligonucleotide is delivered to one or more brain regions selected from the group consisting of the striatum, the cerebellum, the brain stem, the hippocampus, the frontal cortex, and the spinal cord.
  • Embodiment P73 A method for treating or ameliorating a disease, disorder, or symptom thereof in a subject, comprising administration of a compound, or salt thereof, of any one of embodiments P1-P69, or a composition of embodiment P70, to the subject.
  • Embodiment P74 The method of embodiment P73, wherein the disease, disorder, or symptom thereof is a central nervous system (CNS) disease, disorder, or symptom thereof.
  • CNS central nervous system
  • Embodiment P75 The method of embodiment P73 or P74, wherein the disease, disorder, or symptom thereof is Alzheimer’s disease, or a symptom thereof.
  • Embodiment P76 The method of any one of embodiments P71-P75, wherein the compound, or salt thereof, is administered to the subject intrathecally.
  • Embodiment P77 A method for making a compound, or salt thereof, of any one of embodiments P1-P69, comprising one or more compounds and chemical transformations described herein, including Example 1.
  • Additional embodiments include embodiment 1 to embodiment 135 following.
  • Embodiment 1 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, comprising the structure of Formula (V):
  • Formula (V) wherein: each are independently a Tropomyosin receptor B (TrkB) ligand; each of L 1 , L 2 , L 3 , L 4 , L 1 , L 2 , L 3 , and L 4 is independently a linker, bond, or absent;
  • TrkB Tropomyosin receptor B
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide; zl is 1, 2, or 3; and zl' is 0, 1, 2, or 3.
  • Embodiment 2 The compound of embodiment 1, or a stereoisomer, tautomer, prodrug, or salt thereof, wherein: zl is 1; and zl' is 0 or 1.
  • Embodiment 3 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 2, wherein zl is 1 and zl' is 0.
  • Embodiment 4 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-3, wherein the compound comprises the structure of Formula (I):
  • Embodiment 5 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 4, comprising the structure of Formula (I'): wherein:
  • — — — — — is an oligonucleotide.
  • Embodiment 6 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 1 or 2, wherein zl and zl' are each independently 1.
  • Embodiment 7 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 6, wherein the compound comprises the structure of Formula (VI):
  • Embodiment 8 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 7, wherein the compound comprises the structure of Formula (VI'): wherein:
  • Embodiment 9 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-8, wherein the TrkB ligand comprises a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycle, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted cycloalkyl.
  • Embodiment 10 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-9, wherein the TrkB ligand comprises a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.
  • Embodiment 11 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-10, wherein the TrkB ligand comprises a substituted or unsubstituted mono- or polycyclic aryl, substituted or unsubstituted mono- or polycyclic heteroaryl, substituted or unsubstituted mono- or polycyclic heterocycloalkyl, or substituted or unsubstituted mono- or polycyclic cycloalkyl.
  • Embodiment 12 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 11, wherein the substituted or unsubstituted polycyclic aryl, substituted or unsubstituted polycyclic heteroaryl, substituted or unsubstituted polycyclic heterocycloalkyl or substituted or unsubstituted mono- or polycyclic cycloalkyl are a fused ring system.
  • Embodiment 13 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 12, wherein the fused ring system comprises two to four fused rings.
  • Embodiment 14 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 13, wherein the fused ring system further comprises an optionally substituted pendant cycloalkyl, optionally substituted pendant heterocycloalkyl, optionally substituted pendant aryl, or an optionally substituted pendant heteroaryl.
  • Embodiment 15 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-14, wherein each TrkB ligand is independently:
  • R 2 is hydrogen, -OR 7 , -SR 8 , or -NR 9 R 10 ;
  • R 3 is hydrogen, -OR 31 , -SR 32 , or -NR 33 R 34 ;
  • R 4 is hydrogen, -OR 35 , -SR 36 , or -NR 37 R 38 ;
  • R 5 is hydrogen, -OR 39 , -SR 40 , or -NR 41 R 42 ;
  • R 7 , R 8 , R 9 , R 10 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , and R 42 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl;
  • Y is CH 2 , NH, S, or O
  • Z is optionally substituted aryl or optionally substituted heteroaryl
  • R 11 and R 13 are each independently absent, hydrogen, or optionally substituted alkyl
  • R 12 , R 14 , and R 15 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 16 is hydrogen, halogen, -CN, -N3, -SO ni6 R 1A , -SO v i6NR 16B R 16C , -NHNR 16B R 16C , -ONR 16B R 16C , -NHC(O)NHNR 16B R 16C , -NHC(O)NR 16B R 16C , -N(0)mi6, -NR 16B R 16C , - C(0)R 16D , -C(0)0R 16D , -C(O)NR 16B R 16C , -0R 16A , -NR 16B SO 2 R 16A , -NR 16B C(O)R 16D ;
  • R 20 is hydrogen, halogen, -CN, -N 3 , -SO n20 R 1A , -SO V 2oNR 20B R 20C , -NHNR 20B R 20C , -ONR 20B R 20C , -NHC(O)NHNR 20B R 20C , -NHC(O)NR 20B R 20C , -N(O)m20, -NR 20B R 20C , -C(O)R 20D , -C(O)OR 20D , -C(O)NR 20B R 20C , -OR 20A , -NR 20B SO 2 R 20A , -NR 20B C(O)R 20D ;
  • -NR 20B C(O)OR 20D -NR 20B OR 20D , optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 21 is hydrogen, halogen, -CN, -N 3 , -SO n2 iR 1A , -SO V2 INR 21B R 21C , -NHNR 21B R 21C , -ONR 21B R 21C , -NHC(O)NHNR 21B R 21C , -NHC(O)NR 21B R 21C , -N(0)m2i, -NR 21B R 21C , -C(O)R 21D , -C(O)OR 21D , -C(O)NR 21B R 21C , -OR 21A , -NR 21B SO 2 R 21A , -NR 21B C(O)R 21D ;
  • -NR 21B C(O)OR 21D optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 22 and R 23 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 24 is hydrogen, halogen, -CN, -N 3 , -SO n24 R 1A , -SO v2 4NR 24B R 24C , -NHNR 24B R 24C , -ONR 24B R 24C , -NHC(O)NHNR 24B R 24C , -NHC(O)NR 24B R 24C , -N(O)m24, -NR 24B R 24C , -C(O)R 24D , -C(O)OR 24D , -C(O)NR 24B R 24C , -OR 24A , -NR 24B SO 2 R 24A , -NR 24B C(O)R 24D ;
  • -NR 24B C(O)OR 24D -NR 24B OR 24D , optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 20A , R 20B , R 20C , R 20D , R 21A , R 21B , R 21C , R 21D , R 24A , R 24B , R 24C , and R 24D are each independently hydrogen, halogen, -CF 3 , -CC1 3 , -CBr 3 , -CI 3 ,-COOH, -CONH 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 20B , R 20C , R 21B , R 21C , R 24B , R 24C , R 24B , and R 24C substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or
  • Embodiment 16 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-15, wherein each TrkB ligand is independently flavone, tropoflavin, or derivatives thereof.
  • Embodiment 17 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-16, wherein each TrkB ligand is independently 3,7-dihydroxyflavone, 3,7,8,2'-tetrahydroxyflavone, 7,3'-dihydroxyflavone, 7,8,2'-trihydroxyflavone, 7,8,3'- trihydroxyflavone, 7,8,4'-trihydroxyflavone, diosmetin (5,7,3'-trihydroxy-4'-methoxyflavone), 7- hydroxy-4'-methoxyflavone, 8-hydroxy-7-methoxyflavone, eutropoflavin (4'-dimethylamino-7,8- dihydroxy flavone), norwogonin (5,7,8-trihydroxyflavone), R7, R13, tropoflavin (7,8- dihydroxy flavone), quercetin (3,3',4
  • Embodiment 18 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, comprising the structure of Formula (II):
  • R 2 is hydrogen, -OR 7 , -SR 8 , or -NR 9 R 10 ;
  • R 3 is hydrogen, -OR 31 , -SR 32 , or -NR 33 R 34 ;
  • R 4 is hydrogen, -OR 35 , -SR 36 , or -NR 37 R 38 ;
  • R 5 is hydrogen, -OR 39 , -SR 40 , or -NR 41 R 42 ;
  • R 7 , R 8 , R 9 , R 10 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , and R 42 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl;
  • Y is CH 2 , NH, S, or O
  • Z is optionally substituted aryl or optionally substituted heteroaryl.
  • Embodiment 19 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 18, wherein the compound comprises the structure of Formula (Il-a):
  • Embodiment 20 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 18, wherein the compound comprises the structure of Formula (Il-b):
  • Embodiment 21 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 18, wherein the compound comprises the structure of Formula (II-c):
  • Embodiment 22 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 15-21, wherein R 2 is -OH.
  • Embodiment 23 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 15-22, wherein R 3 is -OH.
  • Embodiment 24 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 15-23, wherein R 4 is hydrogen.
  • Embodiment 25 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 15-24, wherein R 5 is hydrogen.
  • Embodiment 27 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 15-26, wherein Y is O.
  • Embodiment 28 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 15-27, wherein Z is optionally substituted aryl.
  • Embodiment 29 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 15-28, wherein Z is optionally substituted phenyl.
  • Embodiment 30 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 15-29, wherein Z is unsubstituted phenyl.
  • Embodiment 31 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 15-29, wherein Z is phenyl substituted with one or more -OH and/or -O- alkyl.
  • Embodiment 32 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, wherein the compound comprises the structure of Formula (III):
  • Embodiment 33 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 32, wherein the compound comprises the structure of Formula (Ill-a):
  • Embodiment 34 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 32, wherein the compound comprises the structure of Formula (Ill-b):
  • Embodiment 35 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 32, wherein the compound comprises the structure of Formula (III-c):
  • Embodiment 36 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 35, wherein the compound comprises the structure of Formula (III-c- 1):
  • Embodiment 37 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-36, wherein the TrkB ligand is ANA- 12, or a prodrug or derivative thereof
  • Embodiment 38 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, wherein the compound comprises the structure of Formula (IF):
  • each of E 1 , L 2 , L 3 , and L 4 is independently a linker, bond, or absent;
  • R 2 is hydrogen, -OR 7 , -SR 8 , or -NR 9 R 10 ;
  • R 3 is hydrogen, -OR 31 , -SR 32 , or -NR 33 R 34 ;
  • R 4 is hydrogen, -OR 35 , -SR 36 , or -NR 37 R 38 ;
  • R 5 is hydrogen, -OR 39 , -SR 40 , or -NR 41 R 42 ;
  • R 7 , R 8 , R 9 , R 10 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , and R 42 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl;
  • Y is CH 2 , NH, S, or O
  • Z is optionally substituted aryl or optionally substituted heteroaryl; and is an oligonucleotide.
  • Embodiment 39 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, wherein the compound comprises the structure of Formula (II"):
  • each of L 1 , L 2 , L 3 , L 4 , L 1 , L 2 , L 3 , and L 4 is independently a linker, bond, or absent;
  • R 2 is hydrogen, -OR 7 , -SR 8 , or -NR 9 R 10 ;
  • R 2 is hydrogen, -OR 7 , -SR 8 , or -NR 9 R 10 ;
  • R 3 is hydrogen, -OR 31 , -SR 32 , or -NR 33 R 34 ;
  • R 3 is hydrogen, -OR 31 , -SR 32 , or -NR 33 R 34 ;
  • R 4 is hydrogen, -OR 35 , -SR 36 , or -NR 37 R 38 ;
  • R 4 is hydrogen, -OR 35 , -SR 36 , or -NR 37 R 38 ;
  • R 5 is hydrogen, -OR 39 , -SR 40 , or -NR 41 R 42 ;
  • R 5 is hydrogen, -OR 39 , -SR 40 ', or -NR 41 R 42 ;
  • R 37 , R 38 , R 38 , R 39 , R 39 , R 40 , R 40 , R 41 , R 41 , R 42 , and R 42 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl;
  • Y and Y' are each independently CH2, NH, S, or O;
  • Embodiment 40 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, comprising the structure of Formula (IV):
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide.
  • Embodiment 41 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 40, wherein the compound comprises the structure of Formula (IV-a):
  • Embodiment 42 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 40, wherein the compound comprises the structure of Formula (IV-b):
  • Embodiment 43 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, comprising the structure of Formula (VII): wherein: each of L 1 , L 2 , L 3 , and L 4 is independently a linker, bond, or absent;
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide;
  • R 11 and R 13 are each independently absent, hydrogen, or optionally substituted alkyl
  • R 12 , R 14 , and R 15 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 16 is hydrogen, halogen, -CN, -N 3 , -SO ni6 R 1A , -SO v i6NR 16B R 16C , -NHNR 16B R 16C , -ONR 16B R 16C , -NHC(O)NHNR 16B R 16C , -NHC(O)NR 16B R 16C , -N(0)mi6, -NR 16B R 16C , -C(O)R 16D , -C(O)OR 16D , -C(O)NR 16B R 16C , -OR 16A , -NR 16B SO 2 R 16A , -NR 16B C(O)R 16D ;
  • R 16A , R 16B , R 16C , R 16D are each independently hydrogen, halogen, -CF3, -CCI3, -CBr 3 , -CI3, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 16B and R 16C substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; z3 is 0, 1, 2, 3, 4, or 5; nl6 is 0, 1, 2, 3, or 4; and vl6 and ml 6 are each independently 1 or 2.
  • Embodiment 44 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 43, wherein the compound comprises the structure of Formula (VII- a), Formula (Vll-b), or a mixture thereof:
  • Embodiment 45 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 44, wherein the compound comprises the structure of Formula (VII-c):
  • Embodiment 46 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 44 or 45, wherein the compound comprises the structure of Formula (VII-c- 1), Formula (VII-c-2), or a mixture thereof:
  • Embodiment 47 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 46, wherein R 16 is hydrogen, optionally substituted alkyl, or optionally substituted heteroalkyl.
  • Embodiment 48 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 46 or 47, wherein:
  • R 16 is -NR 16B R 16C ;
  • R 16B and R 16C are each independently hydrogen or optionally substituted alkyl.
  • Embodiment 49 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 48, wherein:
  • R 16B is hydrogen
  • R 16C is C1-C3 alkyl.
  • Embodiment 50 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 49, wherein R 16C is -CH3.
  • Embodiment 51 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 43, wherein the compound comprises the structure of Formula (Vll-d):
  • Embodiment 52 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 43 or 51, wherein the compound comprises the structure of Formula (VII-d-1), Formula (VII-d-2), or a mixture thereof:
  • Embodiment 53 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 52, wherein R 12 is hydrogen or optionally substituted alkyl.
  • Embodiment 54 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 53, wherein R 12 is hydrogen or C1-C3 alkyl.
  • Embodiment 55 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 54, wherein R 12 is hydrogen or -CH3.
  • Embodiment 56 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, wherein the compound comprises the structure of Formula (II"):
  • Formula (II) wherein: oligonucleotide; each of L 1 , L 2 , L 3 , L 4 , L 1 , L 2 , L 3 , and L 4 is independently a linker, bond, or absent;
  • R 2 is hydrogen, -OR 7 , -SR 8 , or -NR 9 R 10 ;
  • R 3 is hydrogen, -OR 31 , -SR 32 , or -NR 33 R 34 ;
  • R 4 is hydrogen, -OR 35 , -SR 36 , or -NR 37 R 38 ;
  • R 5 is hydrogen, -OR 39 , -SR 40 , or -NR 41 R 42 ;
  • R 7 , R 8 , R 9 , R 10 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , and R 42 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl;
  • Y is CH 2 , NH, S, or O
  • Z is optionally substituted aryl or optionally substituted heteroaryl
  • R 11 and R 13 are each independently absent, hydrogen, or optionally substituted alkyl
  • Embodiment 57 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, wherein the compound comprises the structure of Formula (II'"):
  • each of E 1 , L 2 , L 3 , L 4 or L 1 , L 2 , L 3 , and L 4 is independently a linker, bond, or absent;
  • R n , R ir , R 13 , and R 13 are each independently absent, hydrogen, or optionally substituted alkyl;
  • Embodiment 58 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, comprising the structure of Formula (VIII):
  • each of L 1 , L 2 , L 3 , and L 4 is independently a linker, bond, or absent;
  • R 17 , R 18 , and R 19 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; z4 is 0, 1, or 2; and z5 is 0, 1, 2, or 3.
  • Embodiment 59 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 58, wherein the compound comprises the structure of Formula (Vlll-a):
  • R 18 1 is hydrogen, optionally substituted alkyl or optionally substituted heteroalkyl.
  • Embodiment 61 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, comprising the structure of Formula (IX):
  • each of L 1 , L 2 , L 3 , and L 4 is independently a linker, bond, or absent;
  • R 20 is hydrogen, halogen, -CN, -N 3 , -SO n20 R 1A , -SO V 2oNR 20B R 20C , -NHNR 20B R 20C , -ONR 20B R 20C , -NHC(O)NHNR 20B R 20C , -NHC(O)NR 20B R 20C , -N(O)m20, -NR 20B R 20C , -C(O)R 20D , -C(O)OR 20D , -C(O)NR 20B R 20C , -OR 20A , -NR 20B SO 2 R 20A , -NR 20B C(O)R 20D ;
  • -NR 20B C(O)OR 20D -NR 20B OR 20D , optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 21 is hydrogen, halogen, -CN, -N 3 , -SO n2 iR 1A , -SO V2 INR 21B R 21C , -NHNR 21B R 21C , -ONR 21B R 21C , -NHC(O)NHNR 21B R 21C , -NHC(O)NR 21B R 21C , -N(0)m2i, -NR 21B R 21C , -C(O)R 21D , -C(O)OR 21D , -C(O)NR 21B R 21C , -OR 21A , -NR 21B SO 2 R 21A , -NR 21B C(O)R 21D ;
  • -NR 21B C(O)OR 21D optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 22 and R 23 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 24 is hydrogen, halogen, -CN, -N 3 , -SO n2 4R 24A , -SO V 24NR 24B R 24C , -NHNR 24B R 24C , -ONR 24B R 24C , -NHC(O)NHNR 24B R 24C , -NHC(O)NR 24B R 24C , -N(O)m24, -NR 24B R 24C , -C(O)R 24D , -C(O)OR 24D , -C(O)NR 24B R 24C , -OR 24A , -NR 24B SO 2 R 24A , -NR 24B C(O)R 24D ;
  • -NR 24B C(O)OR 24D -NR 24B OR 24D , optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 20A , R 20B , R 20C , R 20D , R 21A , R 21B , R 21C , R 21D , R 24A , R 24B , R 24C , and R 24D are each independently hydrogen, halogen, -CF3, -CCI3, -CBr 3 , -CI3 -COOH, -CONH 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 20B , R 20C , R 21B , R 21C , R 24B , R 24C , R 24B , and R 2 4C substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstit
  • Embodiment 62 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 61, wherein the compound comprises the structure of Formula (IX-a):
  • Embodiment 63 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 61 or 62, wherein the compound comprises the structure of Formula (IX-a-1):
  • R 24B and R 24C are each independently optionally substituted alkyl or optionally substituted heteroalkyl; and ml is 1, 2, or 3.
  • Embodiment 64 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 61-63, wherein the compound comprises the structure of Formula (IX-a- 2):
  • Embodiment 65 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 64, wherein R 24B is hydrogen or optionally substituted alkyl.
  • Embodiment 66 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 65, wherein R 24B is C1-C3 alkyl.
  • Embodiment 67 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 66, wherein R 24B is -CH3.
  • Embodiment 68 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, comprising the structure of Formula (X):
  • each of L 1 , L 2 , L 3 , and L 4 is independently a linker, bond, or absent; and R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide.
  • Embodiment 69 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 70, wherein the compound comprises the structure of Formula (X-a):
  • each of L 1 , L 2 , L 3 , and L 4 is independently a linker, bond, or absent;
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide.
  • Embodiment 70 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, comprising the structure of Formula (XI): each of L 1 , L 2 , L 3 , and L 4 is independently a linker, bond, or absent; andR 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide.
  • Embodiment 71 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 70, wherein the compound comprises the structure of Formula (Xl-a):
  • Embodiment 72 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-71, wherein the TrkB ligand is a TrkB agonist, a TrkB partial agonist, or a TrkB antagonist.
  • Embodiment 73 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-71, wherein the TrkB ligand is a TrkB selective ligand or a TrkB non- selective ligand.
  • Embodiment 74 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-73, wherein each L 1 , L 2 , L 3 , L 4 , L 1 , L 2 , L 3 , and L 4 are each independently absent, a bond, an optionally substituted alkyl linker, an optionally substituted polyethylene glycol (PEG) linker, an optionally substituted heteroalkyl linker, or an optionally substituted heteroaryl linker.
  • PEG polyethylene glycol
  • Embodiment 75 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 74, wherein L 1 and L 1 are each independently an optionally substituted heteroaryl linker.
  • Embodiment 76 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 74, wherein L 1 and L 1 are each independently an optionally substituted unsaturated heteroaryl, an optionally substituted heteroaryl or an optionally substituted saturated or partially unsaturated heterocycloalkyl linker.
  • Embodiment 77 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of
  • Embodiment 78 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 74, wherein L 1 and L 1 are each independently an optionally substituted heteroalkyl linker.
  • Embodiment 79 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 78, wherein the optionally substituted heteroalkyl linker is an optionally substituted heteroalkyl or optionally substituted Ci-Cio alkyl chain in which one or more carbon atoms are replaced with O, N, or S.
  • the optionally substituted heteroalkyl linker is an optionally substituted heteroalkyl or optionally substituted Ci-Cio alkyl chain in which one or more carbon atoms are replaced with O, N, or S.
  • Embodiment 80 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of
  • L 1 and L 1 each independently comprise the structure or
  • Embodiment 81 The compound, of salt thereof, of embodiment 78 or 79, wherein L 1 and
  • L 1 each independently comprise the structure or -N(CH3)-.
  • Embodiment 82 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 74-81, wherein L 2 and L 2 are each independently an optionally substituted PEG linker.
  • Embodiment 83 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 82, wherein the PEG linker is five PEG units in length.
  • Embodiment 84 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 82, wherein the PEG linker is four PEG units in length.
  • Embodiment 85 The compound, of salt thereof, of embodiment 82, wherein the PEG linker is three PEG units in length.
  • Embodiment 86 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 74-85, wherein L 2 and L 2 are each independently an optionally substituted alkyl linker.
  • Embodiment 87 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 86, wherein L 2 and L 2 are each independently an optionally substituted Ci-20 alkyl linker.
  • Embodiment 88 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 86 or 87, wherein L 2 and L 2 are each independently an optionally substituted Cs alkyl linker.
  • Embodiment 89 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 76-88, wherein L 3 and L 3 are each independently is an optionally substituted heteroaryl linker.
  • Embodiment 90 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 89, wherein L 3 and L 3 are each independently an optionally substituted partially unsaturated heteroaryl linker, an optionally substituted heteroaryl or an optionally substituted saturated or partially unsaturated heterocycloalkyl linker.
  • Embodiment 91 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 90, wherein L 3 and L 3 each independently comprise the structure
  • Embodiment 92 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 74-91, wherein L 4 and L 4 are each independently an optionally substituted heteroalkyl linker.
  • Embodiment 94 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 92 or 93, wherein the heteroalkyl linker comprises two substituents joined together to form an optionally substituted carbocyclyl ring.
  • Embodiment 95 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiment 92-94, wherein L 4 and L 4 each independently comprise the structure salt thereof, wherein X is O or S.
  • Embodiment 96 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 92-94, wherein L 4 and L 4 each independently comprise the structure: wherein X is O or S.
  • Embodiment 97 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-96, wherein L 1 - L 2 -L 3 -L 4 ; or L ⁇ L ⁇ L ⁇ L 4 each independently comprise the structure:
  • Embodiment 98 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, wherein the compound comprises the structure:
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide
  • X is O or S.
  • Embodiment 99 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, wherein the compound comprises the structure:
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide
  • X is O or S.
  • Embodiment 100 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, wherein the compound comprises the structure:
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide
  • X is O or S.
  • Embodiment 101 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, wherein the compound comprises the structure: wherein:
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide
  • X is O or S.
  • Embodiment 102 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 97-101, wherein X is O.
  • Embodiment 103 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 97-101, wherein X is S.
  • Embodiment 104 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-103, wherein R 1 comprises an oligonucleotide.
  • Embodiment 105 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 104, wherein the oligonucleotide is attached at its 5' end.
  • Embodiment 106 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 104, wherein the oligonucleotide is attached at its 3' end.
  • Embodiment 107 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 104, wherein the oligonucleotide is attached at an internal position on the oligonucleotide.
  • Embodiment 108 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 104, wherein the internal position is an intemucleoside linkage.
  • Embodiment 109 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-108, wherein R 1 comprises an oligonucleotide conjugated to one or more additional TrkB ligands.
  • Embodiment 110 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 109, wherein the oligonucleotide is conjugated to two, three, four, five, or more than five additional TrkB ligands.
  • Embodiment 111 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 109 or 110, wherein the additional TrkB ligands are conjugated to the oligonucleotide at the 5' end of the oligonucleotide, the 3' end of the oligonucleotide, the 5'- and 3' ends of the oligonucleotide, one or more internal positions on the oligonucleotide, or any combination thereof.
  • Embodiment 112 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-111, wherein the oligonucleotide is a modified oligonucleotide.
  • Embodiment 113 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, wherein the compound comprises the structure:
  • Embodiment 114 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, wherein the compound comprises the structure:
  • Embodiment 115 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-114, wherein the compound is a salt.
  • Embodiment 116 The compound, or a stereoisomer, tautomer, prodrug thereof, of embodiment 115, wherein the salt is a potassium salt or a sodium salt.
  • Embodiment 117 A composition comprising a compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-116, and a pharmaceutically acceptable excipient.
  • Embodiment 118 A method for delivering a therapeutic oligonucleotide to the brain of a subject, comprising administration of a compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-116, or a composition of embodiment 117, to the subject.
  • Embodiment 119 The method of embodiment 118, wherein the therapeutic oligonucleotide is delivered to one or more brain regions selected from the group consisting of the striatum, the cerebellum, the brain stem, the hippocampus, the frontal cortex, and the spinal cord.
  • Embodiment 120 Embodiment 120.
  • a method for treating or ameliorating a disease, disorder, or symptom thereof in a subject comprising administration of a compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-116, or a composition of embodiment 117, to the subject.
  • Embodiment 121 The method of embodiment 120, wherein the disease, disorder, or symptom thereof is a central nervous system (CNS) disease, disorder, or symptom thereof.
  • CNS central nervous system
  • Embodiment 122 The method of embodiment 120 or 121, wherein the disease, disorder, or symptom thereof is Alzheimer’s disease, or a symptom thereof.
  • Embodiment 123 The method of any one of embodiments 118-122, wherein the administration is intrathecal administration or intracerebroventricular (ICV) administration.
  • ICV intracerebroventricular
  • Embodiment 124 A method of delivering one or more cargo molecules to a cell or tissue of a subject in vivo, comprising administering to the subject a compound of any one of embodiments 1-116 or a composition of embodiment 117.
  • Embodiment 125 The method of embodiment 124, wherein the cell or tissue is CNS cell or tissue.
  • Embodiment 126 A precursor compound, or a stereoisomer, tautomer, or salt thereof, of any one of structural Formulae (A)-(F):
  • each of L 1 , L 2 , L 3 , and L 4 is independently a linker, bond, or absent;
  • R 2 is hydrogen, -OR 7 , -SR 8 , or -NR 9 R 10 ;
  • R 3 is hydrogen, -OR 31 , -SR 32 , or -NR 33 R 34 ;
  • R 4 is hydrogen, -OR 35 , -SR 36 , or -NR 37 R 38 ;
  • R 5 is hydrogen, -OR 39 , -SR 40 , or -NR 41 R 42 ;
  • R 7 , R 8 , R 9 , R 10 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , and R 42 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl;
  • Y is CH 2 , NH, S, or O;
  • Z is optionally substituted aryl or optionally substituted heteroaryl;
  • R 11 and R 13 are each independently absent, hydrogen, or optionally substituted alkyl
  • R 12 , R 14 , and R 15 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 16 is hydrogen, halogen, -CN, -N 3 , -SO ni6 R 1A , -SO v i6NR 16B R 16C , -NHNR 16B R 16C , -ONR 16B R 16C , -NHC(O)NHNR 16B R 16C , -NHC(O)NR 16B R 16C , -N(0)mi6, -NR 16B R 16C , -C(O)R 16D , -C(O)OR 16D , -C(O)NR 16B R 16C , -OR 16A , -NR 16B SO 2 R 16A , -NR 16B C(O)R 16D ;
  • R 16A , R 16B , R 16C , R 16D are each independently hydrogen, halogen, -CF3, -CCI3, -CBr 3 , -CI3, -COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 16B and R 16C substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
  • R 17 , R 18 , and R 19 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 20 is hydrogen, halogen, -CN, -N3, -SO n20 R 1A , -SO v2 oNR 20B R 20C , -NHNR 20B R 20C , -ONR 20B R 20C , -NHC(O)NHNR 20B R 20C , -NHC(O)NR 20B R 20C , -N(O)m20, -NR 20B R 20C , -C(O)R 20D , -C(O)OR 20D , -C(O)NR 20B R 20C , -OR 20A , -NR 20B SO 2 R 20A , -NR 20B C(O)R 20D ;
  • R 21 is hydrogen, halogen, -CN, -N 3 , -SO n2 iR 1A , -SO V 2iNR 21B R 21c , -NHNR 21B R 21C , -ONR 21B R 21C , -NHC(O)NHNR 21B R 21C , -NHC(O)NR 21B R 21C , -N(0)m2i, -NR 21B R 21C , -C(O)R 21D , -C(O)OR 21D , -C(O)NR 21B R 21C , -OR 21A , -NR 21B SO 2 R 21A , -NR 21B SO 2 R 21A , -NR 21B SO 2 R 21A , -NR 21B SO 2 R 21A , -NR 21B SO 2 R 21A , -NR 21B SO 2 R 21A , -NR 21B SO 2 R 21A , -NR 21B SO 2 R 21A
  • -NR 21B C(O)OR 21D optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 22 and R 23 are each independently hydrogen, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 24 is hydrogen, halogen, -CN, -N 3 , -SO n 2 4 R 1A , -SO V 24NR 24B R 24C , -NHNR 24B R 24C , -ONR 24B R 24C , -NHC(O)NHNR 24B R 24C , -NHC(O)NR 24B R 24C , -N(O)m24, -NR 24B R 24C , -C(O)R 24D , -C(O)OR 24D , -C(O)NR 24B R 24C , -OR 24A , -NR 24B SO 2 R 24A , -NR 24B C(O)R 24D ;
  • -NR 24B C(O)OR 24D -NR 24B OR 24D , optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;
  • R 20A , R 20B , R 20C , R 20D , R 21A , R 21B , R 21C , R 21D , R 24A , R 24B , R 24C , and R 24D are each independently hydrogen, halogen, -CF 3 , -CC1 3 , -CBr 3 , -CI 3 ,-COOH, -CONH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 20B , R 20C , R 21B , R 21C , R 24B , R 24C , R 24B , and R 2 4C substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or un
  • Embodiment 127 A method for making a compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 1-116, comprising contacting the precursor compound of embodiment 126 with a compound of structural Formula (G) and/or (H): salt thereof, wherein:
  • X 7 and X 8 are each independently 0 or S;
  • R 1 is an oligonucleotide, a protecting group, a small molecule, a protein, an antibody, or a peptide.
  • Embodiment 128 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, wherein the compound comprises the structure:
  • X is S or O
  • — — — — — is an oligonucleotide.
  • Embodiment 129 A precursor compound, or a stereoisomer, tautomer, or salt thereof, wherein the compound comprises the structure:
  • Embodiment 130 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, wherein the compound comprises the structure:
  • — — — — — is an oligonucleotide
  • X is 0 or S.
  • Embodiment 131 A compound, or a stereoisomer, tautomer, prodrug, or salt thereof, wherein the compound comprises the structure:
  • X is 0 or S.
  • Embodiment 132 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 130 or 131, wherein X is O.
  • Embodiment 132 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 130 or 131, wherein X is S.
  • Embodiment 133 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of any one of embodiments 130-132, wherein the compound is in salt form.
  • Embodiment 134 The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 133, wherein the salt is a sodium salt.
  • Embodiment 135. The compound, or a stereoisomer, tautomer, prodrug, or salt thereof, of embodiment 133, wherein the salt is a potassium salt.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PCT/US2023/062436 2022-02-11 2023-02-10 Trkb ligand conjugated compounds and uses thereof Ceased WO2023154896A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US18/837,377 US20250161459A1 (en) 2022-02-11 2023-02-10 Trkb ligand conjugated compounds and uses thereof
KR1020247029980A KR20240159828A (ko) 2022-02-11 2023-02-10 Trkb 리간드 접합 화합물 및 이의 용도
EP23753724.6A EP4475837A2 (en) 2022-02-11 2023-02-10 Trkb ligand conjugated compounds and uses thereof
AU2023218398A AU2023218398A1 (en) 2022-02-11 2023-02-10 Trkb ligand conjugated compounds and uses thereof
IL314847A IL314847A (en) 2022-02-11 2023-02-10 TRKB Nigand Conjugate Compounds and Their Uses
CN202380033092.0A CN118973616A (zh) 2022-02-11 2023-02-10 TrkB配体缀合的化合物及其用途
CA3251455A CA3251455A1 (en) 2022-02-11 2023-02-10 TRKB LIGAND CONJUGATED COMPOUNDS AND THEIR USES
JP2024547694A JP2025506186A (ja) 2022-02-11 2023-02-10 Trkbリガンドコンジュゲート化合物及びその使用
MX2024009892A MX2024009892A (es) 2022-02-11 2024-08-12 Compuestos conjugados con ligando trkb y usos de estos

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202263309337P 2022-02-11 2022-02-11
US63/309,337 2022-02-11
US202263327342P 2022-04-04 2022-04-04
US63/327,342 2022-04-04
US202263335150P 2022-04-26 2022-04-26
US63/335,150 2022-04-26
US202263352809P 2022-06-16 2022-06-16
US63/352,809 2022-06-16

Publications (2)

Publication Number Publication Date
WO2023154896A2 true WO2023154896A2 (en) 2023-08-17
WO2023154896A3 WO2023154896A3 (en) 2023-09-28

Family

ID=87565161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/062436 Ceased WO2023154896A2 (en) 2022-02-11 2023-02-10 Trkb ligand conjugated compounds and uses thereof

Country Status (9)

Country Link
US (1) US20250161459A1 (cg-RX-API-DMAC10.html)
EP (1) EP4475837A2 (cg-RX-API-DMAC10.html)
JP (1) JP2025506186A (cg-RX-API-DMAC10.html)
KR (1) KR20240159828A (cg-RX-API-DMAC10.html)
AU (1) AU2023218398A1 (cg-RX-API-DMAC10.html)
CA (1) CA3251455A1 (cg-RX-API-DMAC10.html)
IL (1) IL314847A (cg-RX-API-DMAC10.html)
MX (1) MX2024009892A (cg-RX-API-DMAC10.html)
WO (1) WO2023154896A2 (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024220930A3 (en) * 2023-04-20 2024-12-26 Adarx Pharmaceuticals, Inc. Mapt-modulating compositions and methods of use thereof
WO2025038971A1 (en) * 2023-08-17 2025-02-20 Adarx Pharmaceuticals, Inc. Oligonucleotides containing a ligand at a nucleobase, 2' position, or 3' position
WO2025157804A1 (en) * 2024-01-24 2025-07-31 F. Hoffmann-La Roche Ag Linkers for site-specific protein conjugation
WO2026057077A1 (zh) * 2024-09-14 2026-03-19 厦门甘宝利生物医药有限公司 一种多靶点rna抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0381902A1 (en) * 1989-01-09 1990-08-16 Merrell Dow Pharmaceuticals Inc. Tetralin derivatives
US7166755B2 (en) * 2004-09-30 2007-01-23 Air Products And Chemicals, Inc. Synthesis of pentafluorosulfanylnaphthalene

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024220930A3 (en) * 2023-04-20 2024-12-26 Adarx Pharmaceuticals, Inc. Mapt-modulating compositions and methods of use thereof
WO2025038971A1 (en) * 2023-08-17 2025-02-20 Adarx Pharmaceuticals, Inc. Oligonucleotides containing a ligand at a nucleobase, 2' position, or 3' position
WO2025157804A1 (en) * 2024-01-24 2025-07-31 F. Hoffmann-La Roche Ag Linkers for site-specific protein conjugation
WO2026057077A1 (zh) * 2024-09-14 2026-03-19 厦门甘宝利生物医药有限公司 一种多靶点rna抑制剂

Also Published As

Publication number Publication date
CA3251455A1 (en) 2023-08-17
KR20240159828A (ko) 2024-11-06
MX2024009892A (es) 2024-12-06
EP4475837A2 (en) 2024-12-18
JP2025506186A (ja) 2025-03-07
WO2023154896A3 (en) 2023-09-28
AU2023218398A1 (en) 2024-08-29
US20250161459A1 (en) 2025-05-22
IL314847A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
EP4475837A2 (en) Trkb ligand conjugated compounds and uses thereof
EP4486336A2 (en) Cb1 ligand conjugated compounds and uses thereof
US20260000775A1 (en) a4ß1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF
WO2025038971A1 (en) Oligonucleotides containing a ligand at a nucleobase, 2' position, or 3' position
CN118973616A (zh) TrkB配体缀合的化合物及其用途
HK40115097A (en) Trkb ligand conjugated compounds and uses thereof
WO2024238396A1 (en) Nmda ligand conjugated compounds and uses thereof
US20250312367A1 (en) Oligonucleotides having a synthetic backbone and synthesis thereof
WO2025199428A1 (en) Mannose receptor ligand-tropomyosin receptor b ligand conjugates for drug delivery
AU2024324374A1 (en) Oligonucleotides containing a ligand at an internal position
WO2025038963A1 (en) Oligonucleotides containing multiple ligands and/or lipids
WO2026090357A1 (en) Mapt-modulating oligonucleotides for treating central nervous system diseases
HK40119467A (en) α4β1/7INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF
HK40116537A (en) Cb1 ligand conjugated compounds and uses thereof
KR20260074284A (ko) 다수의 올리고뉴클레오티드를 함유하는 변형된 올리고뉴클레오티드

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23753724

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2024/009892

Country of ref document: MX

Ref document number: AU23218398

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2024547694

Country of ref document: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112024016354

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202417064918

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2023218398

Country of ref document: AU

Date of ref document: 20230210

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2023753724

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023753724

Country of ref document: EP

Effective date: 20240911

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23753724

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11202405436Q

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 202380033092.0

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 112024016354

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20240809

WWP Wipo information: published in national office

Ref document number: 18837377

Country of ref document: US